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Esophageal and gastroesophageal junction adenocarcinoma (GEJ) is a rapidly increasing 
deadly disease with a pathophysiology that is connected to oxidative stress. Exact 
pretreatment clinical staging is essential for optimal care of this lethal malignancy. 
Because of the rising incidence of the disease and the expense of new treatments, the cost-
effectiveness of treatment is increasingly important. The aim of this study was to assess 
the protective effect of antirefl ux surgery against oxidative stress of esophageal mucosa, 
the role of oxidative DNA-damage (8-hydroxydeoxyguanosine) in the pathogenesis of 
Barrett’s esophagus and adenocarcinoma of the distal esophagus and GEJ, and the accuracy 
and a prognostic value of positron emission tomography (PET) in preoperative staging of 
adenocarcinoma of the esophagus and GEJ. In addition, we estimated the cost-utility of 
the present treatment schema for adenocarcinoma of the esophagus and GEJ.
We measured oxidative metabolism in the distal and proximal esophagus by 
myeloperoxidase activity (MPA), glutathione content (GSH), and superoxide dismutase 
(SOD) in 20 patients operated on with Nissen fundoplication and in 9 controls 
during a 4-year follow-up. Further, we assessed the oxidative damage of DNA by 8-
hydroxydeoxyguanosine (8-OHdG) in esophageal samples of 51 subjects (13 Barrett’s 
metaplasia, 6 Barrett’s esophagus with high-grade dysplasia, 18 adenocarcinoma of the 
distal esophagus/GEJ, and 14 normal controls). We estimated the accuracy (42 patients) 
and preoperative prognostic value (55 patients) of PET compared with computed 
tomography (CT) and endoscopic ultrasound (EUS) in patients with adenocarcinoma 
of the esophagus or the GEJ. Finally, we clarifi ed the specialty-related costs and the utility 
of either radical (30 patients) or palliative (23 patients) treatment of esophageal/GEJ 
carcinoma by the 15D health-related quality-of-life (HRQoL) questionnaire and survival 
rate. The cost-utility of radical treatment of esophageal/GEJ carcinoma was investigated 
using a decision tree analysis model comparing radical, palliative, and hypothetical new 
treatment.
Despite successful antirefl ux surgery, oxidative stress (measured by MPA) in the 
distal esophagus remained higher in patients than in controls at 6 months and 4 years 
postoperatively. Antioxidative capacity of distal esophageal mucosa measured by GSH 
levels was lower than control levels both pre- and postoperatively. In spite of decreased 
oxidative stress (MPA) in the proximal esophagus, GERD patients had defi cient 
antioxidative capacity before and after fundoplication compared with controls, refl ected as 
decreased GSH and SOD levels both preoperatively and 4 years postoperatively. Oxidative 
stress-related DNA damage (as 8-OHdG) in the distal esophagus was markedly increased 
in Barrett’s epithelium and in high-grade dysplasia as well as in adenocarcinoma of the 
esophagus/GEJ compared with controls. Barrett’s patients had similar 8-OHdG levels in 
their distal and proximal esophageal samples.
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PET was no better in detection locoregional lymph node metastasis than CT or EUS, 
but PET was more sensitive than CT in identifying distant organ metastases. Unfortunately, 
some false-negative diagnoses of stage IV disease (distant metastases) were made even 
with PET. Positive PET for distant metastasis predicted well the poor survival of these 
patients. Despite increasing costs, taking into consideration the improved survival and 
quality of life of treated patients, the incremental cost-utility ratio of the radical surgery 
strategy compared with non-surgical options was favorable during the 2-year follow-up 
period.
Elevated oxidative stress (MPA) and decreased antioxidant defense (GSH) after 
antirefl ux surgery in the distal esophagus indicate that antirefl ux surgery is not a perfect 
solution for oxidative stress of the esophageal mucosa. Elevated oxidative stress in turn 
may partly explain why adenocarcinoma of the distal esophagus is found even after 
successful fundoplication. In GERD patients, the proximal esophageal mucosal anti-
oxidative defense seems to be defective before and even years after successful antirefl ux 
surgery. In addition, antirefl ux surgery apparently does not change the level of oxidative 
stress in the proximal esophagus, suggesting that defective mucosal anti-oxidative capacity 
plays an important role in development of oxidative damage to the esophageal mucosa in 
GERD. In the malignant transformation of Barrett’s esophagus, an important component 
appears to be oxidative stress. DNA damage may to be mediated by 8-OHdG, and the entire 
esophagus of Barrett’s patients suffers from increased oxidative stress. PET is a useful tool 
in the staging and prognostication of adenocarcinoma of the esophagus/GEJ, detecting 
organ metastases better than CT, although its accuracy in staging of paratumoral and 
distant lymph nodes is limited. Radical surgery for esophageal/GEJ carcinoma provides 
the greatest benefi t in terms of survival, and its cost-utility appers to be the best currently 
available treatments. While waiting for new, more effective treatments, radical surgery 
serves as the gold standard for all other treatments.
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INTRODUCTION
Once a very uncommon tumor, adenocarcinoma of the esophagus is currently a cancer 
with a rapidly rising incidence in several Western countries, including Finland (Powell et al. 
1990, Armstrong and Borman 1996, Devesa et al. 1998, Botterweck et al. 2000, Sihvo et al. 
2000, Bollschweiler et al. 2001, van Blankenstein et al. 2005, Voutilainen and Juhola 2005). 
It has replaced squamous cell carcinoma as the most common esophageal malignancy 
in the many industrialized countries (Pohl et al. 2005). The highest reported incidence 
is 7/100,000 in the United Kingdom, and the average incidence in the United States is 
2.5/100 000, although in some regions the incidence in white men is as high as 5.3/100 000 
(Bollschweiler et al. 2001). In Finland, the incidence rose from 0.28 to 0.77/100 000 in males 
during 1976-95 (Sihvo et al. 2000). Similar to esophageal adenocarcinoma, the incidence 
of adenocarcinoma of the gastroesophageal junction (GEJ) has increased signifi cantly 
since the mid-1970s (Blot et al. 1991), although the average rate after the late 1980s in the 
United States (El-Serag et al. 2002) as well as in Finland has stabilized (Sihvo et al. 2000, 
Finnish Cancer Registry 2005).  The overall 5-year survival can be as high as 40-50% in 
selected patients in the best surgical series (Hagen 2001, Sihvo 2004). Unfortunately, up to 
60% of patients end up receiving palliative treatment because of disseminated disease or 
comorbidities and have a median survival of only 3-4 months (Sihvo 2004). 
The specifi c etiological factor behind the dramatic increase in the prevalence of 
esophageal and GEJ adenocarcinomas is unknown, but an undeniable risk factor for 
adenocarcinoma of the distal esophagus is gastroesophageal refl ux disease (GERD) 
and its consequence, Barrett’s esophagus (Chow et al. 1998, Lagergren et al. 1999). A 
major risk for cancer among those who have GERD is Barrett’s esophagus (Solaymani-
Dodaran et al. 2004). Patients with Barrett’s esophagus have a 30- to 400-fold increased 
risk for developing adenocarcinoma (Spechler and Goyal 1986, Drewitz et al. 1997). 
The annual risk for adenocarcinoma in Barrett’s patients is 0.5% (Shaheen et al. 2000). 
While the increasing length of Barrett’s esophagus may slightly increase the cancer risk, 
the progression of Barrett’s metaplasia to dysplasia is the major risk (DeMeester and 
DeMeester 2000, Rudolph et al. 2000, Conio et al. 2001). Other risk factors that may 
contribute to the rising incidence of esophageal adenocarcinoma are cigarette smoking, 
low intakes of fruit, vegetables, and cereal fi bers, and obesity (Pera 2005).
The risk factors for GEJ adenocarcinoma are controversial. The risk has been suggested 
to invariably be related  to Helicobacter pylori infection (Goldblum 2002, Goldblum et al. 
2002,), but strong evidence indicates that the risk is at least partly connected to GERD 
(Bowrey et al. 1999, Couvelard et al. 2001, DeMeester et al. 2002, Balaji et al. 2003).
The development and maintenance of metaplastic epithelium (Barrett’s esophagus) 
are associated with infi ltration of infl ammatory cells (Weston et al. 1997, Goldblum 
et al. 1998, Harrison et al. 2000). This infi ltration of infl ammatory cells in turn causes 
the increased production of reactive oxygen species (ROS), which can lead to oxidative 
damage to proteins, cell membranes, or most importantly to DNA, producing pro-
mutagenic lesions like 8-hydroxydeoxyguanosine (8-OHDG) (Kasai et al. 1997, Olliver et 
11
al. 2003, Boonstra and Post 2004). Oxidative damage seems to be strongly connected to 
the malignant transformation of Barrett’s esophagus (Olyaee et al. 1995, Oh et al. 2001, 
Sihvo et al. 2002).
The prevention of infl ammation and its sequelae is the ultimate goal of treatment of 
GERD and Barrett’s esophagus. Antirefl ux surgery is very effective in diminishing symptoms 
and macroscopic esophagitis (Desai et al. 2003) and may even induce regression of Barrett’s 
esophagus (Gurski et al. 2002). It may reduce oxidative stress in the distal esophagus in the 
short term (Wetscher et al. 1995), but the long-term effect of fundoplication on oxidative 
stress is unknown. In addition, the preventive effect on adenocarcinoma of the esophagus 
has been refuted by several studies (McDonald et al. 1996, Spechler et al. 2001, Corey et al. 
2002). The role of antirefl ux surgery is still unclear in the prevention of oxidative stress in 
the esophagus. Proton pump inhibitor (PPI) medication has been suggested to slow the 
progression of Barrett’s esophagus to dysplasia and cancer, but not prevent the process 
entirely (Ouatu-Lascar et al. 1999, El-Serag et al. 2004).
New, stage-dependent treatment protocols require the most complete and accurate 
staging possible. For most patients with advanced disease present at diagnosis, the key 
factor for successful treatment of adenocarcinomas near the esophagogastric junction 
is exact pretreatment staging. Unfortunately, the classic combination of endoscopic 
ultrasound (EUS) and thoracic and abdominal computed tomography (CT) scanning 
can detect primary tumors with an accuracy of no more than 66-79%, lymph node 
involvement of 72-82 %, and systemic disease 64% compared with histopathologic 
results obtained from surgery (Salminen et al. 1999, Flamen et al. 2000a, Heidemann et 
al. 2000). Positron emission tomography (PET) is a new staging method based on the 
accumulation of a fl uorinated glucose analog (18F-fl uorodeoxy- D-glucose; FDG) in 
malignant cells (Pauwels et al. 1998), which be observed by a positron camera. PET thus 
provides the opportunity to detect altered tissue metabolism in malignant tumors.  PET 
in combination with CT, provides improved diagnostic accuracy for solid-organ systemic 
metastases (Flamen et al. 2000a, Lerut et al. 2000, Lowe et al. 2005). EUS with fi ne-needle 
aspiration of regional nodes is still investigational (Vazquez-Sequeiros et al. 2003), are 
thoracoscopy and laparoscopy, which can cause tumor seeding of a port site (Freeman et 
al. 2001, Suntharalingam et al. 2001).
Functional well-being of patients has become increasingly important when assessing 
the treatment results of esophageal carcinoma (Blazeby et al. 2001). Treatment is costly 
because of the many different investigations and treatment modalities needed (Soni et al. 
2001). Despite this, cost and cost-utility analyses have been performed to date by very few 
authors in the fi eld of esophageal cancer surgery (Hulscher et al. 2002, Sihvo et al. 2002). 
12
REVIEW OF THE LITERATURE
1. Barrett’s esophagus
1.1. Defi nition
The current defi nition of Barrett’s esophagus includes both endoscopically evident 
displacement of the squamocolumnar junction proximal to the GEJ and the typical 
histological fi nding of normal stratifi ed squamous epithelium lining the esophagus being 
replaced by metaplastic columnar epithelium-containing goblet cells. This epithelium is 
called specialized intestinal metaplasia (Trier 1970, Sharma et al. 2004).  The rationale 
for nomenclature is that dysplasia and adenocarcinoma seem to occur only in intestinal 
mucosa (Lee et al. 1985, Hamilton et al. 1987, Hameeteman et al. 1989, Haggitt 1994). 
1.2. Pathogenesis
The relationship between gastroesophageal refl ux (GER) and the development of Barrett’s 
esophagus is nowadays generally accepted (Hayward 1961, Bremner et al. 1970, Conio et 
al. 2002). The precise mechanism  leading to metaplastic changes in the distal esophagus is, 
however, unclear. Animal studies have clarifi ed that the columnar epithelium is acquired 
when the squamous epithelium is injured; during repair the squamous epithelium 
undergoes columnar metaplasia (Bremner et al. 1970). Although damage to squamous 
mucosa is a necessary factor for the development of columnar metaplasia, a chronically 
abnormal esophageal environment during the period of mucosal repair is essential as well 
(Bremner et al. 1970, Wong and Finckh 1971, Dresner et al. 2003). Gillen et al. (1998) 
have shown that columnar regrowth does not have to ascend from the gastric cardia, as 
previously thought, and Li et al. (1994) suggested that the depth of damage caused by GER 
determines whether regenerating epithelium is columnar or squamous. The acquisition of 
Barrett’s mucosa after the onset of GER following esophagogastrostomy, Heller myotomy, 
and esophagojejunostomy provides further evidence for a relationship between GER 
and Barrett’s esophagus (Naef et al. 1975, Hamilton and Yardley 1977, Meyer et al. 1979, 
Kortan et al. 1981, Westhoff et al. 2004).
Lower esophageal sphincter (LES) hypotension
A defective barrier mechanism between the stomach and the esophagus enables the 
noxious gastroduodenal juice to enter the esophageal mucosa, and this together with 
failing esophageal defenses leads to gastroesophageal refl ux disease (GERD). The failure 
of the barrier can be transient or permanent. Several authors (Dodds et al. 1982, Dent et 
al. 1988, Mittal and McCallum 1988, Mittal et al. 1995) have shown that transient lower 
esophageal sphincter (LES) relaxation is the single most common mechanism in GERD, 
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accounting for 65% of refl ux episodes in refl ux esophagitis patients. The reason for 
refl ux patients having more frequent transient LES relaxation than controls is unknown. 
In 1983, Iascone et al. found patients with Barrett’s esophagus to have worse acid refl ux 
and weaker LES than patients with uncomplicated esophagitis or asymptomatic controls. 
They suggested that Barrett’s esophagus develops as a result of long-standing refl ux 
esophagitis. 
Attwood et al. (1989) reported that 90% of patients with a columnar-lined esophagus 
(CLE) had a mechanically defective LES, and 93% had increased esophageal exposure to 
gastric juice on esophageal pH monitoring. Stein et al. (1990) noted that for GER the critical 
LES pressure is less than 6 mm Hg, overall LES length is less than 2 cm, and abdominal 
LES length is less than 1 cm. It has also been demonstrated by multichannel ambulatory 
24-h pH measurement that as the rate of recorded acid exposure values increase from 
the proximal to distal esophagus, the length of Barrett’s esophagus increases signifi cantly 
(Tharalson et al. 2002).
Hiatal hernias are common among patients with Barrett’s esophagus and are larger 
than among controls or GERD patients with or without esophagitis (Cameron 1999). 
They impair esophageal clearance, cause permanent lowering in LES pressure, and reduce 
the protective effect of the crural diaphragm, thereby predisposing the esophageal mucosa 
to an increased effect of refl uxate (Mittal et al. 1987, Sloan and Kahrilas 1991, Sloan et al. 
1992, Mittal and Balaban 1997).
Motility disturbances in esophagus and stomach
Delayed esophageal clearance in the distal esophagus is common among patients with 
Barrett’s esophagus and thus refl ued material may have a prolonged contact with the 
esophageal mucosa. Kahrilas et al. (1986) showed positive correlation exists between the 
grade of peristaltic dysfunction in the distal esophagus and the grade of esophagitis. It is 
unclear whether this is a primary defect or secondary to acid-induced injury (Eastwood 
et al. 1975, Eckardt 1988, Howard et al. 1994). Fass et al. (2001) has demostrated a defi nite 
positive correlation between the length of Barrett’s esophagus and the duration of 
esophageal acid exposure. Recent Swedish epidemiological studies confi rm the correlation 
between esophageal adenocarcinoma and the duration, frequency, and severity of GER 
symptoms (Lagergren et al. 1999, Ye et al. 2001).
The role of gastric emptying seems to be more unclear. While McCallum et al. (1981) 
found that up to 57% of patients with GERD have impaired gastric emptying, more recent 
studies have demonstrated no difference in the rate of gastric emptying between GERD 
patients with or without esophageal mucosal injury and asymptomatic controls (Shay 
et al. 1987, Keshavarzian et al. 1991). Furthermore, patients with Barrett’s esophagus 
seem to have normal gastric emptying for both solids and liquid bolus (Kogan et al. 1985, 
Johnson et al. 1986). More recently, a multivariate analysis of pathophysiological factors 
in refl ux esophagitis has shown that impaired esophageal acid clearance and hypotonic 
lower esophageal sphincter are the two main independent pathophysiological factors of 
esophagitis, and gastric emptying seems to have no signifi cant role in the development of 
esophagitis (Cadiot et al. 1997).
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Acid, pepcin, and bile
Compared with patients with erosive and nonerosive GERD, patients with Barrett’s 
esophagus typically have greater esophageal acid exposure based on 24-h pH 
monitoring (Iascone et al. 1983, Champion et al. 1994, Coenraad et al. 1998, Neumann 
et al. 1994, Singh et al. 1994, Salminen et al. 1999), but do not have increased basal 
acid output or 24-h or daytime patterns of gastric pH compared with healthy controls 
(Hirschowitz 1996, Savarino et al. 1996). Evidence favoring the important role of acid in 
development of Barrett’s esophagus is that after mucosal ablation of Barrett’s esophagus 
the substitutive mucosa is squamous epithelium with acid suppression, and recurrent 
Barrett’s epitehlium without it (Brandt and Kauvar 1992, Salo et al. 1998, Haag et al. 
1999). The role of pepcin seems to be less signifi cant in the development of mucosal 
injury (Hirschowitz 1996).
Bile refl ux into the esophagus has been suggested by many investigators to be 
an important causative factor in acquisition of Barrett’s esophagus (Halvorsen et al. 
1975, Hamilton and Yardley 1977). Experimental studies have shown that bile salts and 
duodenal contents can cause esophageal mucosal damage (Kivilaakso et al. 1980, Salo 
and Kivilaakso 1983, Martinez de Haro et al. 2001). Duodenogastroesophageal refl ux is 
also increased in Barrett’s esophagus patients, especially in patients with concomitant 
ulcers, strictures, or dysplasia (Attwood et al. 1989). In addition, these same patients 
seem to have simultaneous acid refl ux. Obviously, therefore, both gastric and duodenal 
contents have a role in the pathogenesis of Barrett’s esophagus. The combination of acid 
and bile acid caused the worst mucosal damage according to a recent survey (Oh et al. 
2006).
Cell of origin
Epithelial metaplasia in the distal esophagus is a poorly understood process. There are 
several theories regarding the origin of metaplastic cells. One is that Barrett’s esophagus 
is a result of the upward migration of gastric epithelium after denudation of esophageal 
squamous epithelium (Bremner et al. 1970). This theory is opposed by Gillen et al. (1988) 
who stated that the cell of origin of Barrett’s epithelium is located in esophageal gland ducts 
and is likely to be a multipotent stem cell. The presence of squamous epithelium-related 
cytoceratin 13 in Barrett’s metaplasia supports the origin being the native epithelium (Salo 
et al. 1996). In recent studies, a unique surface cell at the squamocolumnar junction was 
found that has features of both glandular epithelium and squamous epithelium (Shields 
et al. 1993). Furthermore, Boch et al. (1997) reported a new multilayered epithelium 
within Barrett’s epithelium that has histologic characteristics of both squamous and 
columnar epithelia. A study of cytokeratin expression in this multilayered epithelium 
detected columnar and squamous cell markers, indicating an intermediate nature of 
this epithelium (Glickman et al. 2001). This cell type could be the missing link in the 
metaplastic process. Cameron and Arora (2002) suggest that Barrett’s esophagus may 
develop after loss of a long segment of squamous epithelium, with columnar replacement 
in the presence of continuing acid refl ux rather than directly from areas of esophagitis. 
The defi nitive answer of why this stem cell differentiates into columnar cells eludes us.
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Mucosal resistance and the role of saliva
An important supplemental defense against acid in the distal esophagus is the neutralizing 
effect of the saliva (Helm et al. 1984). Saliva also contains several growth factors, including 
epidermal growth factor and transforming growth factor, which have a role in the 
healing of esophageal mucosa (Kongara and Soffer 1999) Saliva may also participate  in 
carcinogenesis near the esophagogastric junction (McColl 2005). The precise role of saliva 
in esophageal defense remains unclear and requires further investigation.
Healthy esophageal mucosa has pre-epithelial, epithelial, and postepithelial defenses. 
Pre-epithelia defenses include the mucus and the unstirred water layer along with surface 
bicarbonate ions. Epithelial defenses consist of the apical cell membrane, junction 
barriers, intracellular and extracellular buffers, and pH regulatory processes. Postepithelial 
defenses involve blood fl ow and the tissue acid-base balance. Patients who are predisposed 
to GER–related injury may have suboptimal mucosal defense (Sarosiek and McCallum 
1995, Kongara and Soffer 1999).
Helicobacter pylori infection
The simultaneous disappearance of H. pylori infection and an increase in refl ux-related 
GEJ adenocarcinoma has raised the question of a possible link between these two events. 
Most studies have found no causal relationship between H. pylori infection and Barrett’s 
esophagus, but some evidence suggests a protective role of H. pylori infection (Werdmuller 
and Loffeld 1997, Varanasi et al. 1998, Vicari et al. 1998).
H. pylori infection has been proposed to protect against the development of Barrett’s 
esophagus because corpus-predominant gastritis is associated with decreased acid 
secretion (El-Serag et al. 1999). This protective effect is especially linked to cagA-positive 
H. pylori strains (Vicari et al. 1998).
Diet, smoking, and alcohol
Low intake or defective absorption of antioxidants such as vitamin C may play a role in 
the development of Barrett’s esophagus (Fountoulakis et al. 2004). Dietary nitrates can be 
converted to nitrosating species by bacteria, saliva, and acidic gastric juice (Mirvish 1995), 
which in turn may deplete antioxidant species, producing oxidative stress. This can cause 
damage to DNA and lead to mutagenesis. The role of alcohol and tobacco smoking in the 
development of Barrett’s esophagus is uncertain, although a few reports connect both of 
these to refl ux disease (Kadakia et al. 1995, Hirota et al. 1999, Pehl et al. 2006). 
In conclusion, the pathogenesis of refl ux esophagitis and Barrett’s esophagus depends 
on defects in either the esophageal antirefl ux barrier or the luminal clearance mechanisms, 
which expose the epithelium  gastroduodenal refl uxate for  prolonged periods. Ingested 
products that directly impair the epithelium’s intrinsic defenses add to the damage, 
compounding vulnerability to injury from refl ux and potentially leading to development 




The endoscopic recognition of Barrett’s esophagus may be diffi cult. Normally, the 
squamous cell junction (Z line) is at the same level as the GEJ, and this can be identifi ed 
as the proximal limit of the linear gastric mucosal folds. When the Z line has transferred 
upwards, the length of Barrett’s esophagus is the distance between the Z line and the 
proximal limit of the linear gastric mucosal folds (Armstrong 2004). The current way of 
describing the extent of Barrett’s esophagus is the Prague C & M criteria, which includes 
assessment of the circumferential (C) and maximum (M) extent of the endoscopically 
visualized BE segment (Sharma  et al. 2006a). The columnar epithelium in the esophagus 
has a characteristic red color and a velvet-like texture that contrasts sharply with the pale, 
glossy appearance of adjacent squamous epithelia. A large hiatal hernia may complicate 
identifi cation of the length of Barrett’s esophagus. Although endoscopic examination can 
usually distinguish columnar epithelium from squamous epithelium in the esophagus, 
the three different subtypes of columnar epithelium lining the esophagus: fundic-
type, cardiac-type, and specialized columnar epithelium (Paull et al. 1976), cannot be 
differentiated based on endoscopic appearance alone. 
The classical distribution of Barrett’s esophagus has been based on the length of Barrett’s 
metaplasia. Barrett’s exceeding 3 cm has been thought to carry a higher risk for malignant 
transformation than shorter measures, but recent studies have shown that the length of 
Barrett’s esophagus is not signifi cantly related to the risk for adenocarcinoma (Rudolph 
et al. 2000, Weston et al. 2000). The clinical relevance of the length of Barrett’s esophagus 
is thus disputable. The histological diagnosis of Barrett’s esophagus often requires both 
hematoxylin and eosin staining (Weinstein et al. 1996) and Alcian blue staining, which 
is specifi c for goblet cells and helps to discriminate between different types of intestinal 
metaplasias (Lee 1984). 
Another diffi culty in diagnosis is the patchy nature of intestinal metaplasia. A linear 
relationship has been demontrated between the prevalence of intestinal metaplasia 
and the length of columnar-lined esophagus. All patients a columnar-lined esophagus 
exceeding 5 cm have intestinal metaplasia, in contrast to only 15% of those whitcolumnar 
segment of less than 1 cm (Chandrasoma et al. 2003). Generally, the number of biopsies 
taken in short-segment Barrett’s esophagus  remains so low that the probability of fi nding 
intestinal metaplasia at initial endoscopy is only 35-45 % (Kim et al. 1994). With increasing 
length, the accuracy improves (Weinstein and Ippoliti 1996). The accuracy of detection 
of intestinal metaplasia also depends on how experienced the endoscopist is (Padda and 
Ramirez 2001), and repeated endoscopies improve the accuracy signifi cantly (Oberg et al. 
2001). Correct diagnosis of intestinal metaplasia involves a combination of endoscopy and 
histology, and often repeated endoscopies are required to rule out intestinal metaplasia if 
suspected at initial endoscopy.
There are a few molecular markers that can help in the diagnosis of Barrett’s esophagus. 
Cdx2 protein is a transcription factor for which expression in normal tissues is restricted 
to intestinal-type epithelium. Its sensitivity seems to be high for Barrett’s esophagus 
(Groisman et al. 2004). The biochemical marker of cellular differentiation mucin 2 
(MUC-2) found in immunohistochemistry can detect intestinal metaplasia as reliably as 
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the Alcian blue-periodic acid-Schiff (AB-PAS) stain detects goblet cells (Lopes et al. 2004). 
The pattern of cytokeratins 7/20 immunoreactivity may help to distinguish cardia-type 
intestinal metaplasia from Barrett’s esophagus, although the results are controversial (El-
Zimaity and Graham 2001).
1.4. Epidemiology 
In 1987, Winters et al. showed that previously undetected Barrett’s esophagus was common 
in people with heartburn. By using the classic 3-cm rule Barrett’s esophagus appears in up 
to 0.5-2% of the general population submitted to esophagogastroduodenoscopy, and up 
to 10% of patients with chronic symptoms of GER (Phillips and Wong 1991). 
Based on an autopsy series, Cameron et al. (1990) estimated the prevalence of 
traditional Barrett’s esophagus in the general population to be 376/100 000. Dulai et al. 
(2002) suggested that for every known patient with Barrett’s, 20 or more unrecognized 
cases may exist  in the general population. If all patients with a biopsy showing intestinal 
metaplasia, regardless of length, were included in the defi nition, then the incidence 
increases from 9% to 32% of unselected patients undergoing upper endoscopy (Cameron 
et al. 1997). In a recent survey, Ronkainen et al. (2005) found the prevalence of Barrett’s 
esophagus of the general Swedish population to be 1.6%. 
According to an epidemiologic survey, the median age for developing Barrett’s 
esophagus is 40 years, although the mean age at diagnosis is 63 years (Cameron and 
Lomboy 1992). Men are overrepresented among Barrett’s esophagus patients, the radio 
being 2-2.5/1 (Gruppo Operativo per lo Studio delle Precancerosi dell’Esofago (GOSPE) 
1991, Cameron and Lomboy 1992, Cook et al. 2005). The length but not the severity of 
symptoms of GERD may predict the development of Barrett’s esophagus (Lieberman et 
al. 1997). The prevalence of Barrett’s esophagus, in a large multicenter study, was reported 
to be 25 times more common among those with refl ux symptoms than among those 
without (GOSPE 1991). On the other hand, up to 40% of Barrett’s esophagus patients with 
simultaneous adenocarcinoma may  have no refl ux symptoms (Williamson et al. 1991). 
The prevalence of Barrett’s esophagus is signifi cantly lower among Asians and blacks 
than among Caucasians living in Western countries, suggesting a role for genetic factors in 
this phenomenon (Hirota et al. 1999, Ford et al. 2005). The role of a genetic predisposition 
in GERD and further in Barrett’s esophagus is supported by the fi nding that fi rst-degree 
relatives of patients with Barrett’s esophagus have up to 4.8-fold more weekly heartburn 
symptoms than matched controls (Trudgill et al. 1999), and long-segment Barrett’s 
esophagus is 2 times more common in relatives of patients with Barrett’s esophagus who 
have refl ux symptoms than in controls with the same symptoms (Romero et al. 2002). 
In an epidemiologic study, familial Barrett’s esophagus could be confi rmed in 7.3% of 
persons with Barrett’s esophagus (Chak et al. 2006). 
Although  adenocarcinoma of the distal esophagus is found with careful pathological 
investigation to be connected to Barrett’s esophagus in 60-95% of cases (Hamilton et al. 
1988, Cameron et al. 1995, Ruol et al. 2000, Theisen et al. 2002), and the incidence of this 
adenocarcinoma has exploded during the last two decades (Powell et al. 1990, Armstrong 
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et al. 1996, Devesa et al. 1998, Sihvo et al. 2000, Bollschweiler et al. 2001), there is no 
conclusive evidence that the prevalence of Barrett’s esophagus has increased markedly 
compared with the number of gastroscopies performed (Caygill et al. 1999, Conio et al. 
2001, Todd et al. 2002).
1.5. Treatment of gastroesophageal refl ux disease on Barrett’s 
esophagus patients 
The treatment of GERD in Barrett’s esophagus patients follows the same guidelines as for 
other refl ux patients. The aim of antirefl ux therapy is to remove the symptoms and signs 
of GERD and to prevent its complications. Usually this approach involves suppressing the 
secretion of gastric acid through the administration of H2-receptor antagonists, or more 
importantly proton-pump inhibitors (DeVault and Castell 1999). Antirefl ux surgery 
creates a barrier to GER through fundoplication (Hinder et al. 1999). These two therapies 
are highly effective in improving or eliminating the symptoms and signs of GERD, but no 
antirefl ux therapy has yet proven to decrease the risk for esophageal adenocarcinoma.
1.6. Dysplasia in Barrett’s esophagus
Abundant evidence suggests that esophageal/GEJ adenocarcinoma develops through a 
dysplasia-carcinoma sequence. Mapping studies have shown dysplasia in mucosa adjacent 
to esophageal/GEJ adenocarcinoma in resected specimens (Spechler and Goyal 1986). 
Follow-up studies have revealed a progression from dysplasia to adenocarcinoma in 
repeated endoscopies with biopsy (Hameeteman et al. 1989, Reid et al. 1992, Sharma et al. 
2006). Therefore, dysplasia in Barrett’s epithelium, and specifi cally high-grade dysplasia, 
is today considered the major risk factor for esophageal/GEJ adenocarcinoma (Reid et al. 
1988, Sharma et al. 2006).
Definition of dysplasia
Dysplasia is defi ned as neoplastic changes in the epithelium that are confi ned to the 
basement membrane of the gland from which they arise (Riddell et al. 1983). Dysplastic 
mucosal changes can be visible or indistinguishable in standard endoscopy. Histologically, 
the typical appearance of dysplasia is hyperchromatic (darker) because dysplastic cells have 
less cytoplasmic mucin and are therefore more basophilic than normal cells. Furthermore, 
nuclear enlargement and crowding that extend a beyond the crypts onto the mucosal 
surface are typical of dysplastic epithelium. The classifi cation of dysplasia of Barrett’s 
esophagus is based on the observation of infl ammatory bowel disease, where the presence 
of dysplasia is defi ned as negative, indefi nite, or positive (Riddell et al. 1983). 
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Diagnosis
With a higher grade of dysplasia, cytologic atypia and architectural distortion become 
more apparent. When this distortion is severe, intramucosal adenocarcinoma is certain. In 
practice, it may be impossible for a pathologist to distinguish between high-grade dysplasia 
and intramucosal adenocarcinoma, especially from endoscopic biopsies (Ormsby et al. 
2002). Inter-observer variation is very common in diagnoses of low-grade dysplasia  (Reid 
et al. 1988, Montgomery et al. 2001). The diffi culty in achieving the correct diagnosis does 
not only apply to the pathologist. Because dysplasia may be present anywhere along a 
Barrett’s esophageal segment and foci can be small or invisible, there is a risk for sampling 
error (Falk et al. 1999). Immunohistochemistry may help to distinguish between dysplastic 
and nondysplastic Barrett’s esophagus by using a-methylacyl-CoAracemase (AMACR), an 
antibody often utilized in the assessment of diagnostically diffi cult atypical and potentially 
neoplastic lesions of the prostate (Dorer et al. 2006).
To improve the reliability of  endoscopy  fi nding  dysplastic foci in Barrett’s esophagus, 
tissue staining methods have been developed in conjunction with magnifying and high-
resolution endoscopes, but their clinical usefulness remains controversial (Connor and 
Sharma 2004). 
Treatment of dysplasia
Dysplasia in Barrett’s epithelium is a concern for both  the patient and the treating 
clinician. The probability of progression low-grade dysplasia to cancer is rather low 
(Sharma et al. 2006), although it seems to be higher than in patients with nondysplastic 
Barrett’s esophagus (1/78 versus 1/278 patient-years of follow-up) (Dulai et al. 2005). 
In long-term surveillance studies (up to 10 years), the frequency of adenocarcinoma in 
patients with high-grade dysplasia was reported to range from 16% to 27% (Weston et al. 
2000, Schnell et al. 2001). On the other hand, the risk for cancer is as high as 60% among 
those with high-grade dysplasia at initial endoscopy who have a visible lesion in the 
esophagus (Tharavej et al. 2006). The extent of dysplasia appears to have a role in the risk 
of cancer (Buttar et al. 2001). In addition, pathological examinations after resection have 
shown unrecognized cancers in 38-73% of all patients undergoing surgery for high-grade 
dysplasia (Peters et al. 1994, Falk et al. 1999, Collard et al. 2002). However, no detectable 
cancers were found within one year of intensive searching, following the diagnosis of 
high-grade dysplasia by Schnell et al.(2001). Endoscopic treatments have been suggested 
to be intermediate options between follow-up and surgery (Sharma et al. 1999, Ell et al. 
2000, Morris et al. 2001, Overholt et al. 2003). 
Because of the diffi culty for pathologists to distinguish adenocarcinoma from high-
grade dysplasia in  endoscopic biopsies, new jumbo biopsies have been advocated to 
improve the accuracy of diagnosis (Ormsby et al. 2002). Despite these new biopsies, up to 
33% of patients undergoing esophagectomy were found to have invasive adenocarcinoma 
(Falk et al. 1999). Therefore, esophagectomy continues to be the gold standard in the 
management of high-grade dysplasia since it removes all Barrett’s esophageal cells, thereby 
decreasing the risk of metacromous and syncronous cancers (Pera et al. 1992, Rice et al. 
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1993, 1998, Stein et al. 2005). Unfortunately,  in-hospital mortality can soar as high as 
14% (mean 2.7%) and morbidity  to 28% (Altorki et al. 1991, Pera et al. 1992, Rice et 
al. 1993, Peters et al. 1994, Heitmiller et al. 1996, Stein et al. 1996, Falk et al. 1999). In 
addition, some patients are poor candidates for major surgery because of their age and 
comorbidity. Endoscopic surveillance strategies are favored because of the low progression 
rate of dysplasia and effective follow-up programs that can detect the development of 
cancer in time (Schnell et al. 2001). The weakness of this strategies is that cancer and 
dysplasia can be multifocal and scattered in patches, and thus can be missed even with 
numerous random biopsies (Cameron et al. 1997). 
Endoscopic treatments are attractive alternatives because of the resultant expected 
low mortality and morbidity. Photodynamic therapy is a nonthermal chemical method 
involving the activation of a photosensitier given to the patient in advance. The 
photosensitizer is activated by a laser light that causes the production of oxygen molecules 
cytotoxic to the mucosa, leading to necrosis. The eradication of high-grade dysplasia can 
be reached in 88% of patients by using a porfi mer or haematoporphyrin derivative and 
neodymium: yttrium-aluminium-garnet laser therapy (Overholt et al. 1999, Wang 2000). 
It is uncertain, however, whether this treatment reduces the incidence of carcinoma, and 
severe strictures can complicate the treatment in up to 60% of cases (Overholt et al. 1999). 
A few studies, involving a small number of patients, have analyzed the effectiveness of laser 
therapy or argon plasma coagulation therapy in the treatment of high-grade dysplasia 
(Sharma et al. 1999, Morris et al. 2001, Van Laethem et al. 2001, Weston et al. 2002). 
Although reported results have been fairly good, with the exception of a couple of major 
complications, these treatments have not become popular.
The mainstream in endoscopic treatments of high-grade dysplasia is endoscopic 
mucosal resection techniques. Several resection techniques have been introduced: with 
or without suction, with or without submucosal injection, cap-assisted, using a variceal-
band ligator, in a single piece (en bloc) or in several fragments (piecemeal) (Ell et al. 2000, 
Nijhawan and Wang 2000, May et al. 2002, May et al. 2003, Seewald et al. 2003, Giovannini 
et al. 2004, Rajan et al. 2004, Vieth et al. 2004). The strength of mucosal resection is that 
removal of full-thickness mucosa enables histological assessment of the lesion. It leads 
to reclassifi cation of the pathological stage in up to 75% of patients, possibly owing to 
biopsy sampling error and inconsistent observer interpretation (Nijhawan and Wang 
2000, Seewald et al. 2003). Endoscopic mucosal resection seems to be a promising tool in 
the treatment of high-grade dysplasia, although long-term follow-up results are needed.
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2. Adenocarcinoma associated with Barrett’s esophagus
2.1. Epidemiology
The incidence of adenocarcinoma of the esophagus is rapidly rising in most Western 
countries (Armstrong and Borman 1996, Devesa et al. 1998, Sihvo et al. 2000, Bollschweiler 
et al. 2001,  El-Serag et al. 2002, Powell et al. 2002, Voutilainen and Juhola 2005). The 
highest estimated incidence rates have been recorded in white males. Between 1992 and 
1996 in the United States, Caucasians were affected fi ve times more than Blacks, and men 
eight times more than women (El-Serag et al. 2002). In 2000, the rates in Great Britain was 
5.0– 8.7/100 000 and in Australia 4.8/100 000 followed by the Netherlands 4.4 cases/100 
000, the United States (3.7/100 000, and Denmark 2.8/100 000. Low rates 1.0/100 000 were 
found in Eastern Europe (Bollschweiler et al. 2001). In Finland, the rate in white males 
had risen from 0.2/100 000 in 1960, to 0.9/100 000  in 1995 (Sihvo et al. 2000). Further, 
the incidence of esophageal adenocarcinoma in men rose tenfold from the 1970s, being 
1.10/100 000/year in 1998-2002. In women, a 4.5-fold increase was observed (0.11/100 
000/year). In 1998-2002, the mean annual number of new esophageal adenocarcinoma 
cases was 57.4 (79.8% men) (Voutilainen and Juhola 2005). Overall, the 5-year survival has 
remained dismal, less than 10%, because the majority of patients present with advanced 
disease at diagnosis, and less than 50% undergo curative treatment (Sihvo et al.  2004).
Risk and preventive factors
The few known risk factors for adenocarcinoma of the esophagus and cardia, besides 
GERD (Lagergren et al. 1999) and its consequence Barrett’s esophagus (Solaymani-
Dodaran et al. 2004), are obesity (Lagergren et al. 1999, Samanic et al. 2004, Samanic et al. 
2006) and  male gender (Hansson et al. 1993, Botterweck et al. 2000), although the exact 
mechanisms by which they increase the risk remain obscure. 
Some factors have been suggested to protect against adenocarcinoma of the distal 
esophagus and cardia. Helicobacter pylori infection may protect against esophageal 
adenocarcinoma (Ye et al. 2004). The role of anti-infl ammatory drugs is controversial 
(Corley et al. 2003, Gonzalez-Perez et al. 2003, Jankowski and Anderson 2004, Lindblad et 
al. 2005, Lagergren 2006). It is generally accepted that high intake of fruit and vegetables 
is inversely associated with the risk of esophageal adenocarcinoma (Terry et al. 2000, 
Chen et al. 2002, Wong and Fitzgerald 2005). Neither antirefl ux medication (Chow et al. 
1995, Farrow al. 2000) nor antirefl ux surgery (Ye et al. 2001) signifi cantly protects against 
adenocarcinoma associated with Barrett’s esophagus. Identifi ed risk factors to date are 
insuffi cient to devise a truly effective prevention program (Lagergren 2006).
2.2. Classifi cation of esophageal and gastroesophageal junctional 
adenocarcinomas
There is general consensus that adenocarcinomas located clearly in the distal esophagus 
and  associated with Barrett’s esophagus are of esophageal origin. When an adenocarcinoma 
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crosses the GEJ, it is very diffi cult to conclude whether it is of esophageal or gastric origin. 
The glandular elements found in tumors are common in the normal proximal stomach, 
the normal distal esophagus, the gastric-type columnar epithelium, and Barrett’s 
esophagus (Spechler 1999). It is therefore impossible to indisputably prove the origin of 
adenocarcinomas at the GEJ. The mucosal line (Z line) between squamous and columnar 
epithelium does not always coincide with the level at which the gastric mucosal folds 
(GEJ) starts. Cardiac mucosa lining of the distal esophagus may be present (Hayward 
1961, Paull et al. 1976). A recent study has shown that the cardiac epithelium may exist 
already in  childhood (Kilgore et al. 2000), and another study revealed that CM develops 
during pregnancy and is present at birth as a normal structure (De Hertogh et al. 2003) 
Paull et al. (1976) postulated that the cardiac epithelium can extend in some cases to 
several centimeters above the GEJ . However a more recent  study showed that the cardiac 
epithelium does not normally extend more than 2-4 mm below the Z line (Kilgore et al. 
2000). Opinions against the inborn nature of cardiac epithelium have also been presented 
(Chandrasoma et al. 2000a, 2000b). 
Adenocarcinoma in the distal esophagus arises from Barrett’s esophagus in the vast 
majority if not in all cases (Hamilton et al. 1988, Clark et al. 1994, Haggitt 1994, Cameron 
et al. 1995, Theisen et al. 2002). The same causality has been suggested for cardiac 
cancers (Clark et al. 1994, Ruol et al. 2000). Many similarities exist concerning GERD 
and H. pylori between carcinomas in the distal esophagus and cardia (MacDonald and 
MacDonald 1987, Parsonnet et al. 1991, Zhang et al. 1996). According to several authors, 
H. pylori is not risk factor for GEJ adenocarcinoma, unlike for gastric cancer (Abbas et al. 
1995, Ricaurte et al. 1996, Asaka et al. 1997). The relationship between adenocarcinoma 
of the esophagus and the GEJ remains controversial. The often asked clinical question 
has the distal esophageal tumor grown downward into the cardia or has the GEJ tumor 
extended proximally into the distal esophagus has no defi nite answer. For practical use, 
the Siewert classifi cation according to the tumor’s location relative to the GEJ provides 
a common language for clinicians. In type I cases, the tumor’s epicenter is located at 
least 1 cm (but no more than 5 cm) above the GEJ, in type II the epicenter is from 1 cm 
above  to 2 cm below the GEJ and in type III the epicenter is between 2 and 5 cm below 
the GEJ (Siewert and Stein 1998). Other investigators have given similar classifi cations 
based on the location of the epicenter of the tumor (Kalish et al. 1984, Mori et al. 1987, 
Husemann 1989, Misumi et al. 1989, Heidl et al. 1993, Clark et al. 1994). The problem 
with this classifi cation is that it presumes that the growth of the tumor is symmetric, 
which is not necessarily the case. Uneven growth may explain the diverse features of 
cardiac cancer which include features of both gastric and esophageal cancers (Clark et al. 
1994). Furthermore, the pathophysiology does not make a clear differentiation between 
adenocarcinoma of the esophagus and the GEJ (Dolan et al. 1999, Cameron et al. 2002). 
The most important factor uniting adenocarcinomas of the distal esophagus and the GEJ 
is the similar distribution of lymph nodes (Dolan et al. 1999, Wijnhoven et al.1999); the 
optimal surgical treatment for both  seems to be the same (Nigro et al.1999, Barbour et 
al. 2007), although Siewert et al. (2000) has advocated gastrectomy and more intensive 
lymphadenectomy intra-abdominally for Type II tumors.
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2.3. Diagnosis
Clinical characteristics and diagnosis 
Predominant symptoms before diagnosis are dysphagia, weight loss, and abdominal pain. 
No symptoms are usually present when the tumor is found at an early stage. Weight loss 
of more than 10% predicts a worse outcome and earlier recurrence after treatment (Mal 
et al. 2005). The diagnosis is typically achieved by endoscopy with biopsy. Barium swallow 
may help to identify the length of stenosis when endoscopy is not feasible because the 
stricture is too tight to pass (Levine et al. 1997). 
Imaging
T stage 
Pretreatment staging of esophageal/GEJ adenocarcinoma comprises assessment of the
depth of tumor invasion (T stage), nodal evaluation (N stage), and distant stage 
evaluation(M stage) (Sobin and Wittekind 1997). Endoscopic ultrasound (EUS) is 
the most useful tool in  T stage assessment, offering an  accuracy of 75-95% of that of 
histopathology in recent studies (Kienle et al. 2002, Luketich et al. 2000). The inability to 
transverse tight malignant strictures, which may occur in up to 45% of patients, decreases 
the overall accuracy of staging (Kelly et al. 2001). EUS plays a very important role in 
identifying patients with advanced locoregional disease (T3, T4, or N1 stage) who may 
benefi t from neoadjuvant therapy. The relatively low spatial and contrast resolution 
of computed tomography (CT) makes it unreliable for assessment of a tumor’s local 
spreading, except in cases where a tracheo-esophageal fi stula or tumor extension into the 
lumen of the airway is present (Hansen et al. 2000, Kienle et al. 2002). Magnetic resonance 
imaging (MRI) is effective, but has not demonstrated any added value over CT and EUS 
in staging of esophageal/GEJ tumors, and is costly compared with EUS (Dave et al. 2004). 
Although functional imaging using PET (positron emission tomography) has been shown 
to be very sensitive 82-100% in detecting primary tumors, its role in  locoregional staging 
is still controversial (Block et al. 1997, Flanagan et al. 1997, Luketich et al. 1997, Kole et al. 
1998, Yeung et al. 1999, Flamen et al. 2000a, Lowe VJ et al. 2005).
N stage 
The detection of correct N stage is very important in the clinical practice. The increasing 
use of neo-adjuvant chemotherapy and new treatment modalities, such as endoscopic 
mucosal resections, requires an exact knowledge of N stage. CT’s accuracy ranges from 
45% to 88% in the staging of mediastinal N disease compared with histopathology (Lerut 
et al. 2000, Nakamura et al. 2002, Weaver et al. 2004). A limitation of CT is that lymph 
nodes may be categorized as suspected malignancies merely because of their size. Lymph 
nodes larger than 10 mm in short-axis diameter on the axial plane are considered suggestive 
of malignancy (Levine et al. 1997). Unfortunately, there may be microscopic tumors in 
normal-sized nodes and an absence of tumors in enlarged, reactive infl ammatory nodes.
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The accuracy of EUS in N staging has been reported to be between 72% and 77% 
(Salminen et al. 1999, Lowe AS et al. 2005), and in combination with helical CT up to 
90% (Lerut et al. 2000, Kienle et al. 2002). EUS-guided fi ne-needle aspiration (FNA) 
biopsy from lymph nodes seems to further enhance the accuracy  (Eloubeidi et al. 2001, 
Romagnuolo et al. 2002). The recent development of lymph node-specifi c contrast agents 
may improve the usefulness of MRI in the staging of medistinal lymph nodes (Imano et 
al. 2004). 
PET’s spatial resolution is 6 mm, which makes it diffi cult for it to discriminate small 
(< 1 cm) lymph nodes near the primary tumor with intense 18-fl uorodeoxyglucose (FDG) 
uptake. The FDG uptake is proportional to the utilization of glucose in the tumor; well-
differentiated carcinomas (G1) are therefore harder to distinguish  poorly differentiated 
carcinomas (G3) (Kato et al. 2005, Miyazaki et al. 2005). Heterogeneous FDG uptake 
in the primary tumor and infl ammatory changes may cause false-positive results. A 
number of reports suggest that PET’s avarage sensitivity and specifi city are 51% and 84%, 
respectively (Block et al. 1997, Flanagan et al. 1997, Luketich 1997, Kole et al. 1998, Yeung 
et al. 1999, Flamen et al. 2000a, Lerut et al. 2000, van Westreenen et al. 2004).
All of the previously presented results highlight the shortcomings of the existing 
imaging modalities in identifying locoregional lymph node metastases (N1) in esophageal/
GEJ adenocarcinoma. Under and overstaging is very common, which limits the accurate 
selection of patients for appropriate therapy. However, keeping in mind the strengths and 
limitations of each diagnostic and staging modality, a rational management strategy can 
be developed for individual patients with esophageal/GEJ adenocarcinoma.
M-Stage
Patients with distant metastases (stage IV disease) the diagnosis do not benefi t from 
surgical treatment, and it is therefore important to identify these patients. Metastases 
most commonly occur in distant lymph nodes (celiac, cervical, supraclavicular), solid 
organs (liver, lung, adrenals), and bone (Quint et al. 1985). The diagnosis of cervical 
and supraclavicular node metastases can be made with a high accuracy (88-89%) 
using ultrasound (van Overhagen et al. 1993, Natsugoe et al. 1999). The recognition of 
pathological celiac nodes is challenging. The accuracy of CT with advances in helical 
technology is around 80% (sensitivity 50%,  specifi city up to 90%) (van Overhagen et al. 
1993, Reed et al. 1999, Romagnuolo et al. 2002).
For diagnosis of distant nodal metastases, FDG-PET alone may be superior to 
combined use of CT and EUS (although accuracy 62% vs. 86%, respectively) due to its 
higher sensitivity and specifi city (Lerut et al. 2000). The best available method for the 
diagnosis of celiac lymph node metastases to date is EUS-guided FNA biopsy applied by 
an expert (sensitivity 98%, specifi city 100%, accuracy 98%) (Eloubeidi et al. 2001).
Several studies have shown that FDG-PET (mean sensitivity 67%, specifi city 97%, 
accuracy 82-94%) is superior to both CT and CT combined with EUS in the identifi cation 
of stage IV disease (Block et al. 1997, Flanagan et al. 1997, Luketich et al. 1997, Kole et 
al. 1998, Flamen et al. 2000a, Lerut et al. 2000, van Westreenen et al. 2004, Lowe VJ et al. 
2005). PET seems to have a signifi cant role in choosing the correct management strategy 
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in 3-20% patients (Block et al. 1997, Luketich et al. 1997, Kole et al. 1998, Yeung et al. 
1999, Flamen et al. 2000a, Lowe VJ et al. 2005). The shortcoming of PET here again is its 
lack of sensitivity in fi nding distant metastatic sites of less than 1 cm (i.e. liver, pancreas, 
peritoneum, micrometastastic deposits in lymph nodes) leading to false-negatives fi ndings 
(Flanagan et al. 1997, Luketich et al. 1999, Flamen et al. 2000a, Kinkel et al. 2002, Lowe VJ 
et al. 2005). Another limitation is that false-positive results in cervical lymph nodes and 
liver are typically due to infl ammatory or infectious processes (Lerut et al. 2000). A false-
positive FDG-PET fi nding could inaccurately exclude patients from curative surgery, and 
therefore, potential metastases need to be confi rmed by histology or cytology. Despite its 
limitations, FDG-PET is currently the most sensitive noninvasive imaging modality for 
the evaluation of non-nodal metastatic disease, although the size of metastasis matters in 
detection of hepatic metastases (Kinkel et al. 2002). Whole-body MRI in a single session 
with the latest generation of multichannel scanners may compete with PET in the detection 
of hepatic and osseous metastases (Lauenstein et al. 2004). On the other hand, the new 
hybrid PET/CT may improve the usefulness of FDG-PET (Larson et al. 2004). Although 
PET seems to be effective in certain cases, ranked according to cost-effi cacy is CT, followed 
by EUS with FNA (Harewood et al. 2002, Wallace et al. 2002, Kneist et al. 2003). Invasive 
staging methods, like thoracoscopy and laparoscopy, have been shown to be effective, but 
are probably too expensive and laborious for general use (Krasna et al. 2001).
prognostic value of preoperative staging 
Despite its limitations, EUS in T and N stagingt is currently the most precise method for 
predicting complete surgical (R0) resection, and thus, the outcome of surgically treated 
esophageal cancer patients (Mariette et al. 2003). CT, by contrast, has limited value in 
predicting the completeness of surgical resection, with an accuracy reaching only 65% 
(Kole et al. 1998). The value of FDG-PET is uncertain. It has been advocated to quite 
accurately predict prognosis based on the intensity of FDG uptake in the primary tumor 
(Fukunaga et al. 1998, Blackstock et al. 2006), but it fails to discriminate between mucosal 
and submucosal tumors on the basis of the intensity of FDG uptake (Little et al. 2007).
Restaging after neoadjuvant therapy
Multimodality treatments that include surgery and chemotherapy with or without 
radiation therapy are used increasingly to treat of esophageal/GEJ adenocarcinoma. 
Choosing the best treatment for each patient is crucial. The response to chemotherapy and/
or radiotherapy has been estimated by using CT and PET. CT seems to be able to identify 
patients with a large amount of residual disease after chemoradiation therapy (CRT) 
(Swisher et al. 2004). However, its ability to recognize the tumor response after induction 
CRT is limited (Jones et al. 1999). The functional characters of FDG–PET provide an 
opportunity to measure tumor activity and response in adenocarcinoma patients before, 
shortly after beginning (2 weeks), and at completion of neoadjuvant therapy (Weber et al. 
2001, Arslan et al. 2002, Flamen et al. 2002, Downey et al. 2003, Wieder  et al. 2005). These 
authors confi rm that a PET scan is much more sensitive than a CT scan in assessing tumor 
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response after chemotherapy as early as 2 weeks after initiation of chemotherapy and at 
all time-points. FDG uptake seems to decrease signifi cantly after successful chemotherapy 
or CRT which has a signifi cant impact on disease-free survival (Downey et al. 2003). PET 
may enable responders to be reliably distinguished from non-responders already after 
2 weeks of treatment (Weber et al. 2001). This has a signifi cant clinical and economic 
impact on the treatment. These fi ndings have been confi rmed in other studies (Kroep 
et al. 2003, Swisher et al. 2004, , Levine et al. 2006, Ott et al. 2006). The shortcomings 
of PET after chemo and/or radiation therapy are that it cannot exclude the presence of 
residual microscopic disease, and therefore, it also cannot exclude the need for esophageal 
resection after defi nitive CRT in eligible patients (Swisher et al. 2004). Another limitation 
is the high rate of false-positive fi ndings, probably because of therapy-induced esophagitis 
(Arslan et al. 2002, Swisher et al. 2004).
Imaging of tumor recurrence
A whole-body CT is the most common method used in follow-up after defi nitive therapy 
for esophageal/GEJ adenocarcinoma (Carlisle et al. 1993, Kantarci et al. 2004). In a 
preliminary report the sensitivities of FDG-PET for the diagnosis of a perianastomotic 
recurrence, diagnosis of regional and distant recurrences were stated to be 100% and 
94%, respectively (Flamen et al. 2000b). Unfortunately, FDG-PET has not been shown to 
provide any survival advantage following earlier treatment of recurrent disease (Flamen 
et al. 2000b).
2.4. Treatment of esophageal and gastroesophageal junctional 
adenocarcinomas
Adenocarcinomas are almost without exception located in the distal esophagus and at the 
GEJ (Devesa et al. 1998, Botterweck et al. 2000, Siewert et al. 2000, Bollschweiler et al. 2001, 
Siewert et al. 2001, Pohl and Welch 2005, van Blankenstein et al. 2005). Patterns of spread of 
esophageal/GEJ adenocarcinoma have been well characterized. The adenocarcinoma invades 
beyond the esophageal wall (T3-T4) to enter the mediastinum (trachea, pericardium, and 
aorta). Spread to cervical, thoracic, and especially upper abdominal lymph nodes is common 
and can skip contiguous stations (Hosch et al. 2001, Mariette et al. 2003). Spread can also 
occur hematogenously, particularly to the liver (Quint et al. 1995).
With surgery an overall 5-year survival of up to 40% can be achieved in eligible patients 
(Hulscher et al. 2001, Johansson et al. 2004), but surgery is accompanied by morbidity as 
high as 60% and in-hospital mortality up to 5% (Hulscher et al. 2002, Johansson et al. 
2004). Advances in surgical techniques together with improvements in perioperative care 
have reduced in-hospital mortality to under 10% in high-volume expert centers (Dimick 
et al. 2005).
The overall prognosis, even for surgically treated patients, is poor because very often 
of diagnosis the tumor has already passed through the wall of the esophagus/cardia, 
and spread of the disease to lymph nodes and/or distant organs has occurred. This poor 
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prognosis is mainly due to patients remaining asymptomatic until dysphagia develops 
from obstruction of the esophageal lumen, a frequent symptom in patients with advanced 
disease. Despite thorough preoperative staging to choose patients for potentially curative 
surgery, many patients experience recurrences within 2 years of esophagectomy (Hulscher 
et al. 2000, de Manzoni et al. 2003, Mariette et al. 2003), and 5-year survival rates rarely 
exceed 25% (Orringer et al. 1999, Hulscher et al. 2001, Hulscher et al. 2002, van Sandick 
et al. 2002). Even with early stage tumors (e.g. submucosal T1b), as many as 30-40% 
of patients will have lymph node metastasis. In T3 tumors, lymph node involvement 
is reported in up to 80% of cases. In addition, the esophageal wall has an extensive 
submucosal lymphatic plexus, which facilitates early dissemination and gives rise to skip 
metastases (Clark et al. 1994). 
Recently, 5-year survival rates in excess of 40% after esophagectomy have been 
presented by specialized centers (Ellis et al. 1997, Hulscher et al. 2002, Sihvo et al. 2004). 
There are also reports which showing favorable trends in postoperative mortality and long-
term survival of large, unselected patient populations who underwent esophagectomy for 
esophageal cancer (Ellis et al. 1997, Hofstetter et al. 2002). Large hospital volume, early 
detection, improved patient selection based on novel staging modalities, and increased 
use of preoperative neoadjuvant therapy are potential explanations for this (Walsh et al. 
1996, Ellis et al. 1997, Stein et al. 2001, Urschel et al. 2003).
Type of operation
It is consistently accepted that patients with adenocarcinoma in the distal esophagus 
(Siewert type I tumors) should undergo esophagectomy. However, the extent of surgical 
resection necessary is disputed (Hulscher et al. 2001). Some authors have suggested that 
better survival will result from aggressive surgery with extended two- or three-fi eld en bloc 
resection (Lerut et al. 1992), while others argue that similar survival with less morbidity 
can be achieved with limited resection (Gockel et al. 2005). The superiority of an extended 
lymphadenectomy is obvious in staging (Lerut et al. 1992, 1999, Hulscher et al. 2001). 
The survival advantage of transthoracic resection seems to be clearer for Siewert type I 
tumors than for type II tumors (Lerut et al. 1999,2004, Hulscher et al. 2001, Altorki et al. 
2002, Hulscher et al. 2002, D’Journo et al. 2005). Extended total gastrectomy (with lower 
morbidity rates than transhiatal resection) has also been suggested adequate in patients 
with type II tumors (Lerut et al. 1992, 1999, Hulscher et al. 2001). Further randomized 
studies are, however, needed on this issue (Siewert et al. 2005). Irrespective of the chosen 
esophagectomy method, the completeness of surgical resection (R 0 resection) is a 
uniform determinant of long-term survival after potentially curative resection (Hölscher 
et al. 1995, Nigro et al. 1999).  Siewert et al. (2000) found on 1 002 consecutive patients 
with resected adenocarcinoma of the esophagogastric junction the 5-year survival of 
resected patients in R0 (both macroscopically and microscopically tumor-free resection 




The relative 5-year survival rate for patients with a diagnosis of esophageal or GEJ 
adenocarcinoma in the US from 1995 to 2000 for all stages was 14.3%. The respective rates 
for local, regional, and distant disease at diagnosis were 29.3%, 13.6%, and 3.1% (Jemal et 
al. 2004). Even for those with potentially surgically curative disease, 5-year survival rates 
are only 40% at best in unselected series (Kelsen 2001, Brenner et al. 2004). Interest in 
multimodality treatments, including surgery and chemotherapy with or without radiation 
therapy, has therefore increased.
Preoperative Radiotherapy versus surgery alone
Several studies comparing neoadjuvant radiation plus surgery with surgical resection 
alone have been performed on esophageal squamous cell carcinoma patients. A meta-
analysis of all available trials concluded that neoadjuvant radiotherapy did not improve 
survival and was not recommended (Arnott et al. 1998). 
Preoperative chemotherapy versus surgery alone
The idea behind providing the chemotherapy before surgery is to obtain downstaging 
of the tumor, thus that increasing the proportion of possible R 0 resections. Given 
beforehand, chemotherapy is also belived to be better tolerated with  the tumor reacting 
to therapy more effectively because tumor tissue oxygenation is better, and when the 
therapy is given at an earlier time-point in treatment it prevents further systemic spread 
(Burak et al. 2003, Lordick el al. 2004). Two large phase 3 trials have reported contradictory 
results concerning pre-operative chemotherapy in esophageal cancer. The US Intergroup 
trial found no signifi cant advantage for neoadjuvant chemotherapy, whereas a positive 
effect was observed in the United Kingdom in the Medical Research Council’s (MRC) 
study with improved survival at 2 years (43% vs. 34%) (Kelsen et al. 1998, Oesophageal 
Medical Research Council Oesophageal Cancer Working Party 2002). Preliminary results 
from the United Kingdom MRC trial including potentially resectable adenocarcinoma of 
the stomach, GEJ, and lower esophagus also indicate that preoperative chemotherapy is 
benefi cial, with 5-year survival rates of 36% for the preoperative chemotherapy group and 
23% for the surgery group (Mooney et al. 2005).
Meta-analyses have also produced discrepant fi ndings on this issue. Malthaner et al. 
(2003) reported a survival advantage for preoperative chemotherapy in the 5-year risk 
ratio. In another meta-analysis, statistically signifi cant differences were noted in 1, 2, and 
3-year survival rates (Urschel et al. 2002).
In conclusion, the role of neoadjuvant therapy in the treatment of the esophageal and 
GEJ adenocarcinoma is unclear and warrants further investigations before any conclusive 
recommendations can be made.
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Preoperative chemoradiation and surgery versus surgery alone
Two randomized trials have evaluated preoperative chemoradiation and surgery compared 
with surgery alone in patients with both squamous cell carcinoma and adenocarcinoma 
(Urba et al. 2001, Burmeister et al. 2005), and a third trial limited enrollment to patients 
with adenocarcinoma only (Walsh et al. 1996). Of these three trials, only one found 
an improvement in survival associated with preoperative chemoradiation (Walsh et al. 
1996), but its results have been criticized because of methodological defi ciencies. An 
Australasian Clinical Trials Group reported their results with 256 patients (mixed cell 
type) who had received preoperative chemoradiation. No signifi cant differences were 
noted in overall or disease-free survival (Burmeister et al. 2005). A meta-analysis of nine 
randomized clinical trials (with mixed cell type) was performed on this issue, revieling 
a statistically signifi cant advantage in both 3-year survival rate (OR 0.66, 95%CI  0.47 - 
0.92), and loco-regional recurrence (OR 0.38, 95% CI 0.23 - 0.63) (Urschel et al. 2003). 
These mixed results, as with preoperative chemotherapy, allow no defi nitive 
recommendations to be made regarding preoperative chemoradiation.
Postoperative chemoradiation therapy and surgery versus surgery alone
No randomized clinical trial exists that compares postoperative chemoradiation 
and surgery with surgery alone for patients with adenocarcinoma of the esophagus. 
A US Intergroup trial, INT-0116, assessed this combined treatment alternative in 
a postoperative setting in patients with adenocarcinoma of the stomach and GEJ. 
Approximately 20% of the of 552 patients had tumors located in the cardia or GEJ areas.. 
Signifi cantly better median survival was found in the combined therapy arm (27 months 
vs. 36 months, hazard ratio for death 1.35 (95%CI 1.09 -1.66; P=0.005) (Macdonald 
et al. 2001). Whether it is possible to generalize the results of this trial, which include 
adenocarcinoma of the GEJ, to adenocarcinoma of the thoracic esophagus is unclear.
Postoperative chemotherapy and surgery versus surgery alone
There is no randomized clinical trial study comparing post-operative chemotherapy 
and surgery with surgery alone for patients with adenocarcinoma of the esophagus. 
Three randomized clinical trials compared these modalities in patients with squamous 
cell carcinoma of the esophagus, however, and found no improvement in survival with 
postoperative chemotherapy (Malthaner et al. 2004).
Definitive chemoradiation
Defi nitive chemoradiation therapy refers to chemoradiation therapy given with a curative 
intent without any surgery involved. Currently, defi nitive chemoradiation is used for 
nonsurgical patients if (1.) comorbidity excludes surgery, (2.) the tumor is located in 
the cervical esophagus, and (3.) the disease is too extensive for surgery. In such patients, 
a 2-year survival rate of 38% can be achieved in series including mostly squamous cell 
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carcinomas with chemoradiation alone (al-Sarraf et al. 1997, Minsky et al. 2002). Recently, 
in locally advanced operable esophageal cancers responding to chemoradiation, defi nitive 
chemoradiation has been described as an alternative to surgery because overall survival is 
equal and early mortality including length of hospital care is better with chemo-radiation 
alone (Stahl et al. 2005, Michel et al. 2006). However, these studies have been carried out 
almost solely with squamous carcinoma patients. Further studies are needed to conclude 
whether a patient population exists that will not benefi t more from a three modality 
(surgery included) treatment instead of two-modality treatment (chemoradiation) and 
whether these results are also applicable toadenocarcinoma patients.
In conclusion, the choice of treatment for the esophageal/GEJ adenocarcinoma is 
not straightforward. The recent trend is to fi nd a tailor-made treatment solution for 
each patient depending on the stage of the disease and existing comorbidities. Localized 
esophageal carcinomas can be removed by using an open transthoracic approach 
(combination of laparatomy and right tharcotomy), an open transhiatal approach, the 
combined use of laparoscopy and thoracoscopy, or endoscopic mucosal resections in 
intramucosal tumors. Reconstructive methods include stomach tube, colon interponate, 
and jejunum interponate. An upper anastomosis can be placed intrathoracically or in the 
neck. Multimodality treatments (surgery with chemotherapy with or without radiation 
therapy) may improve overall survival in eligible patients. Choosing the optimal 
treatment for each patient demands precise pretreatment staging. These kinds of highly 
sophisticated treatment plans can be executed only in specialized centers.
2.5. Oxidative stress in development of Barrett’s esophagus and 
adenocarcinoma 
Oxidative damage has been suggested as a likely mechanism for human GERD and possibly 
also for Barrett’s esophagus (Olyaee et al. 1995, Dvorak et al. 2007). Oxidative damage is a 
result of an imbalance between oxidative stress and antioxidative defense. Oxidative stress 
on the esophageal mucosa is caused by reactive oxygen species (ROS), which are chemicals 
including several oxygen metabolites that form by a one- or two-electron reduction of 
oxygen, such as superoxide anion or hydrogen peroxide. Other endogenous ROS, the like 
hydroxyl radicals, can be generated in the presence of such transition metal ions as Fe2+. 
The major source of ROS seems to be infl ammatory cells (Naya et al. 1997, Yamaguchi et 
al. 2005), although a role of esophageal epithelial cells in the production of ROS has been 
proposed (Olyaee et al. 1995). 
Wetscher et al. (1997) found that oxidative stress increased with the grade of 
esophagitis and was highest in Barrett’s esophagus. Antioxidant capacity and superoxide 
dismutase (SOD) activity, decreased as the grade of esophagitis increased, being lowest 
in Barrett’s esophagus with severe esophagitis. Antirefl ux surgery prevented oxidative 
damage in the esophagus. The authors believed that GERD was mediated by oxidative 
damage, and Barrett’s metaplasia was the result of severe oxidative damage. Decreased 
manganese superoxide dismutase (MnSOD) enzyme expression and activity led to 
esophagitis in an animal model (Li et al. 2007). Jimenez et al. (2005) found SOD mucosal 
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activity signifi cantly decreased in patients with esophagitis and Barrett’s esophagus. They 
concluded that a decrease in SOD antioxidant activity, leading to increased mucosal levels 
of superoxide anion and peroxynitrite radicals, may contribute to the development of 
esophageal damage and Barrett’s esophagus in patients with GER (Jimenez et al. 2005). In 
addition, Inayama et al. (2007) showed that besides decreased SOD activity, the reduced 
glutathione content was lowered in rats in experimentally induced refl ux esophagitis and 
esophageal cancer. Furthermore, Hermann et al. (2005) showed that SOD can protect 
against carcinogenesis in Barrett’s esophagus. 
ROS can cause formation of oxidative base adducts such as 8-hydroxydeoxyguanosine 
(8-OHdG), which in turn can lead to DNA mutations, such as cytosine-cytosine (CC) -> 
thymine-thymine (TT)  (Reid et al. 1993,Walch et al. 2000). In addition, guanine:cytosine 
(G:C) to adenine:thymine (A:T) transitions at cytosine and guanine phosphodiester bond 
(CpG) sites of the the p53 gene occur frequently in human esophageal adenocarcinoma. 
In fact, C to T transition is the most commonly seen mutation that is relatively specifi c to 
oxidative damage (Reid et al. 1992, Loeb 1996). A combination of gastric and bile acids 
has been postulated to  cause mutations in mitochondrial DNA as a result of oxidative 
stress (Cocco et al. 1999, Miyazono et al. 2002,). Dvorak et al. (2007) have shown that 
bile acids and low pH induce oxidative DNA damage (8-OHdG) and mitochondrial 
oxidative stress in esophageal cells. In another study, Dvorak et al. (2006) had  found 
Barrett’s esophagus patients to suffer from increased esophageal acid exposure, leading 
to increased oxidative stress.
Other studies have demonstrated that oxidative damage plays an important role 
in the development of esophageal adenocarcinoma (Wetscher et al. 1995, Cheng and 
Yang 2001, Sihvo et al. 2003), and that a higher intake of antioxidants, such as vitamin 
C, beta-carotene, and alpha-tocopherol, is linked with a decreased risk for esophageal 
adenocarcinoma (Li and Mobarhan 2000, Terry et al. 2000, Fountoulakis et al. 2004). 
Recent animal studies using a surgical model of Barrett’s esophagus and esophageal 
adenocarcinoma to induce duodenogastroesophageal refl ux also confi rm the importance 
of oxidative stress in the pathogenesis of Barrett’s esophagus (Chen et al. 2000, Piazuelo 
et al. 2005, Bondeet et al. 2007).
2.6. Cost-effectiveness, cost-utility, and cost-benefi t of treatment of 
esophageal and esophagogastric junction carcinomas
Because of limited resources, health care policy-makers need to take into account the 
economic impact of their decisions. Thus, there is a growing demand for economic 
evaluations of health technologies. The aim of economic evaluations is to aid the process 
of decision-making by establishing the trade-offs for selecting one treatment over 
another. Only a few studies of cancer treatments have investigated the economic impact 
of treatments in the fi eld of esophageal cancer.
There are three main types of economic evaluation. In a cost-effectiveness analysis 
(CEA), effects are determined by a single clinical outcome, such as survival (in terms of 
years or months). Survival differences established in CEA studies of esophageal cancer are 
often small (a matter of months) (Xinopoulos et al. 2004), and it is therefore important 
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to take into account the patients’ quality of life before and after treatments (Homs et al. 
2004). 
A cost-utility analysis (CUA) may therefore be the more suitable method of evaluation. 
CUA is a special form of cost-effectiveness analysis that evaluates incremental costs and 
impacts of an intervention by assessing health effects using quality-adjusted life-years 
(QALYs) (Drummond et al. 1997). QALYs incorporate both length of life and quality of 
life into a single metric and are calculated by summing the time periods an individual 
spends in different health states, weighted by the qualities of the health states (Gold et al. 
1996). Because new therapies are typically more expensive than standard therapies, CUA 
has gained prominence as a method to inform decision-makers who seek to compare the 
trade-off in incremental costs and gains in health conferred by new treatment choices 
within and across disease states.
CUA requires that health outcomes are translated into utilities (Drummond et al. 
1997). Utilities can be elicited directly from patients or clinicians or the general public by 
survey techniques known as “time trade-off” and “standard gamble”. This approach was 
used by McNamee et al. (2004) with esophageal cancer outcomes. Another approach is 
to use a validated instrument, such as the 15D (Sintonen 2001), to record patients’ own 
judgments of their health experience by mailing them specially designed questionnaires at 
intervals throughout the study. The reported estimations (health states) are then assigned 
utility values that have previously been measured in surveys of the general public (Sintonen 
2001). Questionaire 15D is very well suited for calculation of utilities. The uncertainties 
around the utility values should, however, be subjected to sensitivity analyses to explore 
their impact on the direction and magnitude of results.
Cost-benefi t analysis (CBA) by defi nition measures consequences in monetary 
terms, thus enabling a direct comparison between the costs and consequences of a health 
program. This type of analysis directly answers the question of whether a program is 
worthwhile by assessing its net benefi t. CBA studies in the health care literature are rare 
because of diffi culties in assigning a monetary value to health. 
Measuring costs
The assessment of costs includes identifi cation of signifi cant items to be costed, 
measurement of the quantities of resources used, and valuation; i.e. assigning costs or 
prices to resources. Essential to the cost analysis is the perspective of the study. The study 
can be carried out from the viewpoint of service providers, when only direct costs of 
the treatment of patients including hospital costs or primary care costs are  considered 
or from a wider perspective, which includes the views of the patients, their families, or 
carers, costs of traveling to and from the hospital, lost earnings during the time taken 
off work, and other related costs. Other perspectives include those of the government 
or individual ministries, employers, or health insurers. The broadest perspective of all 
is societal. Economic evaluations do not, and cannot, measure all possible costs. For 
example, diagnostic or treatment costs considered to be the same in both arms of a trial 
will have no impact on the cost differences and should be excluded from the analysis. 
Other costs may be disqualifi ed on the grounds that they will not affect preferences. 
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When valuing the resources, it is possible to use either true costs or prices as charged by 
hospitals, which will include a profi t margin, although the latter may introduce biases 
to the study because they also refl ect local demand for services. A common approach to 
deal with this problem is to defl ate prices by a cost-to-charge ratio (Gold et al. 1996). 
Incremental cost-utility ratio (icur) analysis
A strategy that is more effective is also often more costly, thus, the question arises: “How 
much extra do we have to pay for the extra benefi t?” This is addressed by the incremental 
CUA, which identifi es the cost of an extra unit of benefi t in the form of an incremental 
cost-utility ratio (ICUR). 
When the measure of benefi t is in QALYs, as in a CUA, the ratio will be measured in 
cost per QALY gained. In the illustrative CUA example by Martin et al. (2003), the costs 
in euros and the health benefi ts were measured in terms of QALYs gained. The ICUR for 
epoetin-alfa treatment against cancer treatment-induced anemia was £8 851 per QALY 
with a 99% probability of a positive net benefi t in QALYs and a 94% probability of being 
acceptable using a threshold ICUR of £30 000/QALY. 
Sensitivity analysis
Sensitivity analysis investigates in economic evaluations the relative impact of key variables 
and assumptions on the fi ndings. In a one-way sensitivity analysis, the infl uence of a 
particular variable is studied by varying its value across a credible range, while all other 
variables are held at their baseline values. Similarly, a two-way or a multiway sensitivity 
analysis can be executed. Another method is scenario analysis, in which variables are 
simultaneously set to either  the most optimistic or the most pessimistic values, thus 
creating “best-case” or “worst- case” scenarios. The most recent technique is probabilistic 
sensitivity analysis. It is based on a large number of simulations and examines the effect 
on the results by varying basic variables simultaneously in compliance with predefi ned 
parameter estimate distributions. The use of sensitivity analysis can increase the 
generalizability of the study and its value to decision-makers.
Role of modeling in an economic evaluation
Modeling is a technique of merging effectiveness and cost data from different sources.
There are several reasons why modeling in the form of decision trees or state transition 
models (Markov models) is useful in economic evaluation (Buxton et al. 1997), including 
1) to extrapolate outcomes beyond the trial timeframe (e.g. survival), 2) to transform 
intermediate results into fi nal outcomes (e.g. to relate diagnosis to survival), 3) to assemble 
together data from various sources to explore hypothetical options or options which, for 
ethical reasons, cannot be studied in a trial (e.g. a “no treatment” group), and 4) to investigate 
how results of a trial may vary from setting to setting or in a different population. Modeling 
can be used as a supplement, but it is not a substitute for clinical trials. Models are based on 
existing data and are only as good as the data and the underlying hypothesis. 
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AIMS OF THE STUDY
Aims of this study were to assess:
1) the impact of antirefl ux surgery on oxidative stress of esophageal mucosa caused by 
gastroesophageal refl ux disease.
2) the anti-oxidative capacity and oxidative stress of proximal squamous esophageal 
mucosa before and after antirefl ux surgery. 
3) the role of oxidative DNA damage (8-hydroxydeoxyguanosine) in the pathogenesis of 
Barrett’s esophagus and adenocarcinoma of the distal esophagus and esophagogastric 
junction. 
4) the accuracy of preoperative staging of the adenocarcinoma of esophagus and 
esophagogastric junction by positron emission tomography (PET).
5) PET’s role in prognostication and treatment allocation. 





Studies I and II, 20 gastroesophageal refl ux disease (GERD) patients with typical 
symptoms scheduled for Nissen fundoplication at Kanta-Häme Central Hospital, 
Hämeenlinna, Finland underwent a normal clinical work-up with manometry to exclude 
disturbances in esophageal motility, 24-hour pH measurement, and endoscopy. The 
grade of esophagitis was recorded according to Savary-Miller’s grading system (Savary 
and Miller 1978). Controls were 9 subjects who underwent gastroscopy because of diverse 
dyspepsia.
In Study III, subjects consisted of 51 patients treated at Helsinki University Hospital: 
13 had Barrett’s metaplasia (at least 3 cm), 6 had Barrett’s esophagus with high-grade 
dysplasia, 18 had adenocarcinoma of the distal esophagus/esophagogastric junction (10 
in histologically proven Barrett’s esophagus, and 14 were normal controls. Controls were 
patients with neither symptoms nor endoscopic evidence of esophageal pathology. 
In Study IV, 42 consecutive operable patients and in Study V, 55 operable patients with 
histologically proven adenocarcinoma of the esophagus or the esophagogastric junction 
treated at the Division of General Thoracic and Esophageal Surgery in the Department 
of Cardiothoracic Surgery of Helsinki University Central Hospital were examined prior 
to radical esophagectomy and two-fi eld lymphadenectomy by PET in addition to normal 
clinical staging. The sensitivity, specifi city, and accuracy of this new investigation were 
compared with those of CT and EUS using histopathology as a gold standard. In addition, 
in Study V, the long-term survival of patients was evaluated against the  results of clinical 
staging.
In Study VI, 53 patients entering Helsinki University Central Hospital for treatment 
of esophageal or esophagogastric junction carcinoma between May 2002 and October 
2003 were invited to participate and to fi ll in the 15D HRQoL (health-related quality-
of-life) questionnaire. Of these, 30 were treated by radical surgery and 23 by palliative 
means, mostly by self–expandable metallic stents. Approximately 3, 12, and 24 months 
after treatment, a follow-up questionnaire was mailed to all patients who had returned 
the baseline questionnaire.
2. Methods
2.1. Tissue sample collection
Six biopsy samples (four for analysis of oxidative metabolism, two for histopathologic 
examination) for analysis of oxidative metabolism from the distal esophagus and the 
proximal esophagus were taken at 5 cm and 20 cm above the esophagogastric junction 
at gastroscopy before surgery, as well as at 6 months and 4 years after surgery for Studies 
I and II. For analysis of oxidative metabolism, specimens were snap-frozen and stored at 
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-70oC. Histopathological specimens were stained with hematoxylin and eosin by standard 
techniques. Results were confi rmed in questionable cases with Alcian blue staining
pH 2.5. 
For Study III, all samples were taken either at endoscopy (controls, Barrett’s 
metaplasia, or high-grade dysplasia) with Olympus FB-53U-1 forceps (made specifi cally 
for esophageal biopsies) from the distal (5 cm above the esophagogastric junction) and 
proximal esophagus (20 cm above it), or during surgery from the resected specimen 
(cancer patients). From the same esophageal area (the same square centimeter), biopsies for 
measurement of 8-OHdG, and conventional histology were taken. For high-performance 
liquid chromatography (HPLC)-based 8-OHdG analysis, specimens were snap-frozen 
and stored at -70oC. In cases of high-grade dysplasia, the diagnosis was confi rmed by two 
independent pathologists. 
2.2. Analysis of superoxide dismutase (SOD) and myeloperoxidase 
(MP) activities and glutathione content
Myeloperoxidase activity (MPA) was determined by modifi cation of the method of Suzuki 
et al. (1983), in which the enzyme catalyzes the oxidation of 3, 3’, 5, 5’,-tetramethylbenzidine 
by H2O2 to yield a blue chromogen with a maximum wavelength of 655 nm. MP activity 
is expressed as units/milligram protein (U/mg protein). SOD activity, as U/mg protein, 
was determined by the method of Laihia et al. (1983), in which xanthine/xanthine 
oxidase-dependent chemiluminescence was enhanced by both lucinogenin and linoleate. 
Glutathione (GSH) content, expressed as nmol/mg protein, was estimated by Saville’s 
method (Saville 1958).
2.3. Analysis of 8-hydroxydeoxyguanosine (8-OHdG)
DNA from tissue samples was isolated and purifi ed by a DNA purifi cation kit (NucleoSpin 
Tissue, Machereye Nagel and Düren, Germany). Pure DNA (25-70 mg) was solubilized in 
200 ml of HPLC-grade bottled water with 0.1 mM of DFAM (deferoxamine mesylate) 
added to protect the DNA from artifi cial oxidation. These DNA samples were stored at 
-70˚ C until hydrolyzed and analysed.
The pH of DNA samples was adjusted to 5 with 20 ml of 20 mM sodium acetate 
buffer (pH 5.0). DNA was hydrolyzed to nucleotides on incubation with 5.7 U of nuclease 
P1 at 65˚C for 10 minutes. Thereafter, the pH was adjusted to 8 with 20 ml of 1 M Tris-
HCl buffer (pH 8.5), and samples were further hydrolyzed to nucleosides with alkaline 
phosphatase at 37˚ C for 1 hour. Proteins were removed from the sample with centrifugal 
Micropure-EZ fi lters (Millipore, Bedford, MA). Digested DNA samples were stored at 4o 
C before HPLC analysis, which took place within 24 hours. The amount of 8-OHdG was 
determined with HPLC equipped with an electrochemical detector, and deoxyguanosine 
with a UV-detector. The HPLC confi guration was as follows: system controller SCL-10Avp, 
solvent delivery module LC-10ADvp, degasser PGU-14A and Uv-VIS-detector SPD-
10Avp from Shimadzu, Kyoto, Japan, and electrochemical detector Intro from ANTEC 
Leyden, the Netherlands.
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Data from both detectors were acquired by Shimadzu CLASS-VP software. Injection 
volume was 200 ml, and samples were diluted with HPLC-grade water if necessary. The 
nucleosides were separated by a C18 reverse-phase column (Phenomenex Luna C18, 3 mm, 
4.6 × 150 mm). The elution solution was 50 mM citric acid sodium citrate buffer, pH 3.75, 
with 10% methanol (HPLC-grade) and 2 mM NaCl; fl ow rate was 0.8 ml/min, and the 
column was maintained at 30˚ C in a column oven. The cell potential of the electrochemical 
detector was 700 mV and its range 0.2 nA/V. The absorbance of the UV-detector was
290 nm, which increased the amount of deoxyguanosine that could be quantifi ed.
Retention time for 8-OHdG was 9.5 min and for dG 7.2 min. After 12 min of elution 
at a fl ow rate of 0.8 ml/min, the column was washed with a higher fl ow rate of 1.7 ml/min 
for 40 min. After washing, the system was allowed to re-equilibrate for 8 min at a running 
fl ow rate; 8-OHdG and dG standards were injected before and after the samples. The
8-OHdG concentration was expressed as the ratio of 8-OHdG per 105 dG.
2.4. Positron emission tomography (PET) imaging
The radiochemical synthesis of FDG was a modifi cation of the method reported by 
Hamacher et al. (1986). All PET studies were performed after a minimum fast of 6 h. A 
median dose of 370 MBq of FDG was injected into the vein of the forearm, and after a 50-
min uptake period, patients were positioned supine on a scanner couch. PET acquisition 
commenced with a GE Advance scanner (GE Medical Systems, Milwaukee, WI), which 
has an axial fi eld of view of 15 cm and a spatial resolution of 6 mm. The emission scan 
was obtained in 4-5 bed positions (5 min per position), starting from the level of the 
maxilla and moving down to the mid-abdomen. The fi rst 19 patients were imaged without 
transmission correction for photon attenuation. At the beginning of November 2000, the 
imaging protocol was fulfi lled, and post-emission transmission scans after 3 min in the 
same bed positions were acquired. All images were corrected for decay, dead time, and 
photon attenuation and reconstructed in a 128 × 128 matrix, with an ordered subsets 
expected maximum likelihood reconstruction algorithm and four iterations. For patients 
without transmission- corrected scans, standard Hanning-fi ltered back-projection with 
a 0.3 cutoff level was applied for image reconstruction. Transaxial, coronal, and sagittal 
views were visually evaluated on a high-resolution display monitor (SUN workstation; 
Sun Microsystems, Inc., Mountain View, CA). Corresponding diagnostic CT scans of the 
chest and abdomen, as well as radiology reports, were always available, but no direct co-
registration of PET and CT images was performed. All focally increased FDG uptake not 
associated with a known physiological accumulation of tracer was scored on a three-grade 
scale as defi nitively positive, potentially positive, or unlikely positive for cancer. After co-
reading of CT and/or transmission scans, the anatomical localization of the focus was 
included in the evaluation.
2.5. Health-related quality of life (HRQoL) 
HRQoL was measured by the 15D, a generic, 15-dimensional, standardized, self-
administered HRQoL instrument that can serve as both a profi le and a single index score 
38
measure. The 15D questionnaire consists of the following 15 dimensions: Moving, seeing, 
hearing, breathing, sleeping, eating, speech, eliminating, usual activities, mental function, 
discomfort and symptoms, depression, distress, vitality, and sexual activity. A set of utility 
or preference weights, elicited from the general public through a three-stage valuation 
procedure, is used in an additive aggregation formula to generate the utility score, i.e., 
the 15D score (single index number) over all dimensions. The maximum score is 1 (no 
problems on any dimension), and minimum score 0 (being dead).
2.6. Cost-utility
The utility of treatment was estimated by survival and HRQoL counting quality-adjusted 
life-years (QALYs). The costs used for analysis covered all relevant specialty-related 
costs from the Ecomed® clinical patient administration system (Datawell Ltd., Finland) 
including pre- and postoperative outpatient visits to Helsinki University Central Hospital 
because of esophageal cancer. The cost-utility of radical treatment of esophageal carcinoma 
was investigated using a decision tree analysis model comparing radical and palliative 
treatment on one hand and current practice and hypothetical treatment on the other. 
Incremental cost-utility ratio (ICUR) analysis and sensitivity analyses were performed.
2.7. Statistical methods
Values are expressed as median and range unless otherwise stated. All reported p-values 
are based on two-tailed tests without adjustment for multiple comparisons. Statistical 
calculations were carried out with SPSS software, version 11.0 for Windows™  (SPSS, Inc., 
Chicago, IL).
Studies I and II: Differences at different time-points between controls and patients 
were compared using Mann-Whitney U-test while changes between time-points were 
analyzed using Friedman or Wilcoxon test. Spearman rank correlations were used 
to detect associations between changes in pH measurements and MPA, GSH, and 
SOD. Nonparametric methods were applied because of the asymmetrical shape of the 
distributions of variables. 
Study III: Differences between controls and patients were compared by Mann-Whitney 
U-test. Nonparametric methods were applied because of the shape of the distributions of 
variables. Values are expressed as median and range unless otherwise stated.
Studies IV and V: Sensitivity, specifi city, and accuracy were also calculated by standard 
defi nitions and compared by use of the McNemar test. Median survival was calculated 
according to the Kaplan-Meier method, and comparisons of survival times between 
groups were made by the log-rank test.
Study VI: Costs were compared between groups by the Mann-Whitney U-test. Disease-
free survival and overall survival were estimated according to the Kaplan-Meier method. 
For measures of overall survival, the comparisons were performed with the log-rank test.
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RESULTS
1. Antireflux surgery and oxidative stress in the distal and proximal 
esophagus
Pathological 24-hour pH measurements were detectable in every patient preoperatively 
in Studies I and II. Manometry showed no severe disturbances in esophageal motility. 
Preoperatively, all patients had typical symptoms. Endoscopy revealed by Savary-Miller’s 
grading system (Savary and Miller 1978) nonerosive refl ux disease  in 8 and erosive refl ux 
disease  in 12 patients with either Barrett’s esophagus changes or granulation tissue due 
to infl ammation: grade I in 1, grade II in 4, and grade IV esophagitis in 7 (6 Barrett’s 
esophagus, 1 esophageal ulcer)  patients.
After 6 months, no patient had refl ux symptoms. Esophageal acid exposure was 
normalized in all patients after fundoplication. At endoscopy, erosive esophagitis had 
healed in all cases. After 4 years, 19 patients were re-interviewed, 16 of whom underwent 
endoscopy. Of these 16 patients, 15 were asymptomatic. None of the 16 patients showed 
erosive esophagitis. The three interviewed patients who refused to undergo endoscopy 
were asymptomatic. 
Though MPA in the distal esophagus decreased signifi cantly (p<0.05) 4 years after 
successful antirefl ux surgery, it remained higher than that of controls at both 6 months 
and 4 years after surgery (p<0.05) (Figure 1). GSH levels also decreased signifi cantly at 
both 6 months and 4 years (p<0.05) after surgery compared with baseline. At all time-
points, GSH levels in the distal esophagus in patients were signifi cantly lower than in 
controls (p<0.01) (Figure 2). In the distal esophagus, SOD values neither changed nor 
differed signifi cantly from those of controls.
Figure 1. Myeloperoxidase activity (MPA) at the distal esophagus in controls and in patients 
before treatment (preop) and after 6 months (6 mo postop) and 4 years (4 yrs postop) of 
follow-up. NERD = nonerosive refl ux disease. Controls vs. patients p<0.05 (all time-points). 
Patients preop vs. 4 yrs postop: p<0.05.
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Figure 3 a
Figure 2. Glutathione content (GSH) at the distal esophagus in controls and in patients 
before treatment (preop) and aafter 6 months (6 mo postop) and 4 years (4 yrs postop) of 
follow-up. NERD = non-erosive refl ux disease. Controls vs. patients p<0.01 (all time-points). 
Patients preop vs. 6 mo postop and preop vs. 4 yrs postop: p<0.05. (Figures 1 and 2 reprinted 
with permission Am J Gastroenterol 2006;101:222-8. Rantanen TK, Räsänen JV, Sihvo EI, 
Ahotupa MO, Färkkilä MA, Salo JA. The impact of antirefl ux surgery on oxidative stress 
of esophageal mucosa caused by gastroesophageal refl ux disease: 4-yr follow-up study. . 
Copyrigh Wiley-Blackwell)
In spite of decreased oxidative stress (MPA) compared with controls in the proximal 
esophagus (Figure 3a), GERD patients had defi cient antioxidative capacity both before 
and after fundoplication compared with controls, refl ected as decreased GSH and SOD 
levels both preoperatively and 4 years postoperatively (Figure 3b, c).
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Figure 3, a, b, c.
Myeloperoxidase activity (MPA), superoxide dismutase (SOD) and glutahione content 
(GSH) in the proximal esophagus of controls (Prox control) and patients preoperatively 
(Preop), and after 6 months (6 mo postop) and 4 years (4 yrs postop) of follow-up. * p<.05, 
** p<.01 prox control vs  patients preop, 6 mo postop and 4 yrs postop, Median and inter-




At all time-points, MPA of the distal esophagus was also signifi cantly higher than that of 
the proximal esophagus in patients but not in controls (Figure 4) (p < 0.01 and p = NS, 
respectively). 
Figure 4. 
Figure 4. Myeloperoxidase activity (MPA) in the proximal and distal esophagus of controls 
(Prox control and Dist control) and patients preoperatively (Prox preop and Dist preop), and 
after 6 months (Prox 6 mo and Dist 6 mo) and 4 years (Prox 4 yrs and Dist 4 yrs) of follow-
up.Plots as in Fig 3. Prox control vs Dist control, p = NS, Prox preop vs Dist preop,  Prox 6 
mo vs Dist 6 mo, and Prox 4 yrs vs Dist 4 yrs,  ** p < .01 for all
2. Expression of 8-hydroxydeoxyguanosine in esophageal tissues and 
tumors
The amount of oxidative stress-related DNA damage (as 8-OHdG) was signifi cantly 
increased in the distal esophagus both in Barrett’s epithelium 1.26 (0.08-29.47) and in 
high-grade dysplasia 1.35 (1.04-1.65), as well as in adenocarcinoma of the esophagus/
esophagogastric junction 1.08 (0.59-1.94) compared with controls 0.06 (0-4.08) (p=0.002, 
p=0.012, p=0.001, respectively) (Figure 5). Barrett’s patients had similar 8-OHdG levels in 
their distal and proximal esophageal samples. 
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Figure 5. Oxidative DNA damage (8-OHdG/105dG) levels in the distal esophagus of controls 
(Controls) and patients with adenocarcinoma of the distal esophagus/esophagogastric 
junction (Carcinoma), Barrett’s esophagus with high-grade dysplasia (Dysplasia), or Barrett’s 
metaplasia (Barrett). *p<0.05 and **p<0.01, comparison between controls and patients. No 
signifi cant differences were found between samples from Barrett’s epithelium patients with 
or without high-grade dysplasia and adenocarcinoma. Plots display median (horizontal 
bars), 25th and 75th percentiles (lower and upper limits of boxes) and lowest and highest 
values excluding outliers (error bars).
3. Impact of positron emission tomography on clinical staging 
and prognostication of adenocarcinoma of the esophagus and 
esophagogastric junction
Diagnostic sensitivity for the primary tumor was 83% for PET and 67% for CT; for 
local peritumoral lymph node metastasis, it was 37% for PET and 89% for EUS; and for 
distant metastasis, it was 47% for PET and 33% for CT compared with histopathology. 
Diagnostic specifi city for local lymph node metastasis was 100% with PET and 54% with 
EUS, and for distant metastasis, it was 89% with PET and 96% with CT. Accuracy for 
locoregional lymph node metastasis was 63% for PET, 66% for CT, and 75% for EUS, and 
for distant metastasis, it was 74% for PET and 74% for CT (Table 1). Of the 10 patients 
who were considered inoperable during surgery, PET identifi ed 7 and CT 4 (Table 2). 
The false-negative diagnoses of stage IV disease in PET were peritoneal carcinomatosis 
in two patients, abdominal para-aortic cancer growth in one, metastatic lymph nodes by 
the celiac artery in four, and metastases in the pancreas in one. PET showed false-positive 
lymph nodes at the jugulum in three patients.
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Table 1. Detection of distant metastases by positron emission tomography (PET) and 
computed tomography (CT) in 42 patients with adenocarcinoma of the esophagus or 
esophagogastric junction compared with histopathology. 
Sensitivity Specifi city Accuracy
 No./Total no. % No./Total no. % No/Total no. %
PET 7/15 47 24/27 89 31/42 74
CT 5/15 33 26/27 96 31/42 74
Table 2. Findings of computed tomography (CT), positron emission tomography (PET), 
and endoscopic ultrasonography (EUS) for patients with inoperable disease. 
Sites of disease demonstrated by:
Patient
No.
Site of metastatic 
disease which rendered 
tumor unresectable
Biopsy
proven CT PET EUS
13 Liver Yes No distant metastasis Liver No distant metastasis
16 Left adrenal gland Yes Left adrenal gland Left adrenal gland No passage
20 Carcinomatosis Yes Celiac lymph node No distant metastasis No distant 
metastasis
26 Carcinomatosis Yes No distant metastasis Rib No passage
31 Carcinomatosis Yes No distant metastasis No distant metastasis No passage
39 Left supraclavicular 










42 Liver Yes No distant metastasis Liver No passage
43 Pancreas Yes No distant metastasis No distant metastasis No passage
44 Liver Yes No distant metastasis Liver No passage
49 Liver Yes Liver Liver No passage
(Table1 and 2 reprinted with permission from Ann Surg Oncol 2003;10:954-60. Räsänen JV, Sihvo EI, 
Knuuti MJ, Minn HR, Luostarinen ME, Laippala P, Viljanen T, Salo JA. Prospective analysis of accuracy 
of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging 
of adenocarcinoma of the esophagus and the esophagogastric junction. Copyrigh Springer Science and 
Business Media).
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Positron emission tomography (pet) and survival
Median survival was not reached in histopathologically confi rmed non-distant metastases 
(pM-negative) disease (Figure 6a). In the clinical stage without distant metastases, median 
survival was 24 months when disease was detected by any of the imaging techniques alone 
or in combination: CT (95% CI 13-36 months), PET (14-35 months), EUS or CT (13-36 
months), EUS, CT, or PET (14-35 months), and EUS or CT and PET (14-35 months). 
Median survival in clinical or histopathological stage IV disease is shown in Figure 6b. 
Positive PET for distant metastasis together either EUS or CT accurately predicted the 




Figure 6. (a)Kaplan-Meier estimate of survival by pathologic distant metastases (M) stage. 
(b) Median survival in stage IV adenocarcinoma: histopathologically confi rmed distant me-
tastases disease (pM-positive) or in clinically detected disease (computed tomography [CT], 
positron emission tomography [PET], endoscopic ultrasonography [EUS], or a combination 
of these). Survival is shown as months with 95% confi dence interval.
(Reprinted with permission from J Gastrointest Surg 2004;8:988-96. Sihvo EI, Räsänen JV, Knuuti MJ, Minn 
HR, Luostarinen ME, Viljanen T, Färkkila MA, Salo JA. Adenocarcinoma of the esophagus and the esopha-
gogastric junction: positron emission tomography improves staging and prediction of survival in distant but 
not in locoregional disease. Copyright Elsevier). 
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4. Cost-utility of treatment of carcinoma of the esophagus or 
esophagogastric junction
Of  the 30 radically treated  patients, 27, 23, and 16 were alive at 3, 12, and 24 months, 
respectively (median survival 24 months). The corresponding mean 15D scores of survivors 
in the radically treated group at each point of time were 0.82, 0.87, and 0.86. The median 
cost of radical treatment was 32 271 € over a two-year study period. Of the 23 palliatively 
treated patients 17, 4, and 2 were alive at 3, 12, and 24 months (median survival 6 months) 
(p<0.001 compared with the radical group) (Figure 7). The corresponding mean 15D 
scores of survivors in the palliative group at each point of time were 0.80, 0.72 and 0.75, 
respectively. The median cost of palliative treatment was 18 565 € (p<0.01 compared with 
the radical group) over the two year follow-up or until death. The current practice model 
suggested that, on average, radically treated patients would experience 1.198 quality-
adjusted life-years (QALYs) at a cost of 43 000 € over the entire 24-month time-horizon 
of the model and palliatively treated patients 0.418 QALYs at a cost of 25 000 €. The 
incremental cost-utility ratio (ICUR) of the radical treatment was 22 893 € /QALY gained 
compared with palliative treatment. 
Figure 7. Survival of patients with carcinoma of the esophagus or esophagogastric junction 
treated either with radical surgery or palliatively within current practice. 
Sensitivity analyses
Sensitivity analyses showed that in 46% of the simulated cases radical surgery seems to be 
cost-saving, while in 53% of the cases was more costly and more effective than palliative 
treatment for all patients (Figure 8). If willingness to pay for a QALY is 30 000 €, the 
probability of the current treatment is being acceptable is 68% (Figure 9).
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Figure 8. Scatter plot of estimated joint density of incremental costs and incremental effects 
of current practice versus hypothetical treatment by bootstrap resampling (base case). 
Probabilistic sensitivity analysis: a scatter plot that illustrates the uncertainty in the expected 
incremental costs and QALYs gained for current practice versus hypothetical treatment for 
the base case. Practically all bootstrap replicates lie above zero on the QALYs gained axis, 
indicating a high degree of certainty that current practice where eligible patients are treated 
by radical surgery is more effective than hypothetical treatment where all patients are pro-
vided only palliative treatment. Data points from bootstrapping that lie in the “northeast” 
quadrant of the cost-effectiveness plane represent QALYs gain from hypothetical treatment 
at an additional cost. Points that lie in the “southeast” quadrant represent lower costs from 
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Figure 9. Probabilistic sensitivity analysis: cost-effectiveness acceptability curve representing 
the probability that current practice by radical surgery for all eligible patients vs. hypotheti-
cal treatment (where all patients  provided only palliative treatment) for different values of 
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The adenocarcinoma of the esophagus and esophagogastric junction in Western men has 
received increasing attention because of its rapidly incidence and deadly nature (Powell 
et al. 1990, Armstrong and Borman 1996, Devesa et al. 1998, Botterweck et al. 2000, 
Sihvo et al. 2000, van Bollschweiler et al. 2001, Blankenstein et al., Voutilainen and Juhola 
2005). Unfortunately, despite new treatment forms, in the advanced stages of this disease, 
survival after diagnosis remains dismal (Orringer et al. 1999, Hulscher et al. 2001, 2002, 
van Sandick et al. 2002). Only the disease stages limited to the wall of the esophagus or 
cardia and the surrounding lymph tissue warrant radical surgical treatment (Clark et al. 
1994); exact preoperative clinical staging is therefore essential for optimal treatment of this 
lethal malignancy. The precise mechanism behind the development of this malignancy is 
unknown, although gastroesophageal refl ux disease (GERD) and Barrett’s esophagus have 
been recognized as risk factors for years (Lagergren et al. 1999). Because of the rising 
incidence and expense of new treatments, the cost-effectiveness of treatment is becoming 
increasingly important (Xinopoulos et al. 2004).
1. Oxidative stress and antireflux surgery
This study shows that GER patients suffer from increased oxidative stress and decreased 
anti-oxidative defense in their distal esophagus before antirefl ux surgery. In addition, their 
anti-oxidative defense throughout the esophagus seems to be defective. It was surprising 
to fi nd that although macroscopic esophagitis after antirefl ux surgery was already healed 
at 6 months, reduction in MPA and healing at the cellular level apparently take a much 
longer period and do not reach control levels even at 4 years. We can therefore assume that 
even successful fundoplication cannot fully reverse the oxidative stress in the esophagus 
of patients with GERD during a 4-year follow-up. This is contrary to the conclusion of 
Wetscher et al. (1995) who found in their short-term follow-up study that anti-refl ux 
surgery can prevent oxidative stress in esophageal mucosa. However, MPA in the distal 
esophagus decreased signifi cantly after successful antirefl ux surgery.
Our patients had signifi cantly lower GSH values both before and after surgery in 
the distal esophagus than controls, in agreement with van Lieshout et al. (1999), who 
reported signifi cantly lower glutathione content in Barrett’s epithelium than in normal 
esophageal mucosa. Sido et al. (1998) have shown that patients with infl ammatory bowel 
disease have an intestinal GSH defi ciency in the infl amed and noninfl amed ileum because 
of impairment of GSH synthesis. Our results suggest a similar phenomenon in the distal 
esophagus of patients with GERD. Imbalance between anti-oxidative defense and increased 
oxidative stress can lead to increased reactive oxygen species (ROS) (Farhadi et al. 2002, 
Jimenez et al. 2005, Li et al. 2007). In addition to the lack of recovery from oxidative stress 
of the esophageal mucosa during short- to mid-term follow-up, the increasing failure 
rates of fundoplication with recurrent GERD during long-term follow-up (Luostarinen 
1993) indicate that antirefl ux surgery is not a perfect solution for oxidative stress of the 
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esophageal mucosa. Further studies are needed to compare the effect of medical treatment 
versus antirefl ux surgery on oxidative stress. Keeping in mind that oxidative stress is closely 
related to DNA damage, our results may also partially explain why adenocarcinoma of the 
distal esophagus is found even after successful fundoplication (Ye et al. 2001, Tran et al. 
2005). 
Based on our study in GERD patients, anti-oxidative capacity (GSH, SOD) of the 
proximal esophagus was diminished before and even 4 years after successful antirefl ux 
surgery. Oxidative stress (MPA) in the proximal esophagus was preoperatively lower in 
controls and remained so both 6 months and 4 years after fundoplication. The proximal 
esophageal mucosa in patients with GERD therefore appears to be characterized by a 
low level of oxidative stress and a diminished anti-oxidative defense mechanism. Several 
explanations are possible for the continued difference in levels of oxidative stress between 
the distal and proximal esophagus even years after successful antirefl ux surgery. First, 
higher MPA in the distal esophagus may be an irreversible change after a long period 
of GERD. Second, the protective effects of saliva in the upper and lower esophagus may 
differ. Third, this difference may reveal uneven myeloperoxidase activity of neutrophils 
in these parts of the esophagus in response to chemotactic stimuli, as previously shown 
in gingival tissue (Kowolik and Grant 1983). The reason for the lower MPA in the 
proximal esophagus than in controls, even before surgery, remains unclear. The volume, 
neutralizing capacity, or components of saliva may explain the difference between GERD 
patients and controls (Kongara and Soffer 1999). Most importantly, our fi ndings suggest 
that the impaired anti-oxidative capacity of the proximal esophagus may be caused not by 
increased oxidative stress, but rather by changes in the anti-oxidative defense system itself. 
The cause of this phenomenon may be genetic. The defective antioxidative defense in the 
proximal esophagus of GERD patients  may have an important role in the development 
of complicated GERD.
2. Oxidative DNA damage and pathogenesis of esophageal 
adenocarcinoma 
ROS can cause formation of oxidative base adducts, such as 8-OHdG which in turn can 
lead to DNA mutations. Dvorak et al. (2006) have shown that bile acids compined with 
low pH induce oxidative DNA damage (8-OHdG) and mitochondrial oxidative stress in 
esophageal cells.
We observed signs of oxidative DNA damage in Barrett’s metaplasia, in high-grade 
dysplasia, and in adenocarcinoma of the esophagus/esophagogastric junction. The leading 
hypothesis regarding carcinogenesis in adenocarcinoma of the esophagus/esophagogastric 
junction is a metaplasia-dysplasia-carcinoma sequence of malignant transformation 
(Jankowski et al. 2000), in which the molecular mechanisms remain in many respects 
unclear. Tissue damage in esophagitis and in Barrett’s metaplasia has been associated with 
oxidative stress (Olyaee et al. 1995, Oh et al. 2001), and an inverse epidemiological link 
exists between risk for esophageal adenocarcinoma and anti-oxidants (Terry et al. 2000). 
Furthermore, in an animal model of refl ux-related esophageal damage these anti-oxidants 
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have been lower (Oh et al. 2001). Strong evidence thus suggests that oxidative stress may 
cause changes in DNA bases, leading to mutations and further to the development of 
adenocarcinoma.
3. Imaging and optimal treatment and prognosis
Different options, from mucosal resections (Ell et al. 2000, Nijhawan and Wang 2000, 
May et al. 2002, May et al. 2003, Seewald et al. 2003, Giovannini et al. 2004, Rajan et al. 
2004, Vieth et al. 2004) to multimodal therapy (Burak et al. 2003, Lordick el al. 2004), are 
currently available treat esophageal/GEJ adenocarcinoma. Accurate pretreatment staging 
is crucial to enable optimal choice of treatment. Positron emission tomography (PET) is 
based on the accumulation of a fl uorinated glucose analog (18F-fl uorodeoxy-D-glucose; 
FDG) in malignant cells (Pauwels et al. 1998). This can be observed by a positron camera. 
Thus, PET provides the opportunity to detect altered tissue metabolism in malignant 
tumors. This has been thought to detect tumors and metastases more precisely than with 
conventional staging methods, such as computed tomography (CT) and endoscopic 
ultrasonography (EUS). According to our results, PET failed to identify very small primary 
tumors or to detect small-sized metastatic lesions (spatial resolution 6 mm), such as intra-
abdominal carcinomatosis. Moreover  its sensitivity for detecting lymph node metastases 
was inferior to that of EUS. Our fi ndings show that the overall accuracy of PET to detect 
stage IV disease is no better than that of CT. This is mostly because of a lack of sensitivity 
in fi nding distant lymph node metastases and false-positive judgments of cervical lymph 
nodes. 
In conclusion, all of the staging methods used in this study have shortcomings. EUS 
has problems with accuracy in detecting the T and N stages. The development of new high-
frequency probes and EUS with fi ne-needle biopsy may solve these problems in the future. 
CT is insuffi ciently sensitive in detecting distant metastatic lesions and locoregional nodal 
metastasis. PET can identify organ metastases fairly well, but its lack of overall accuracy 
in predicting distant metastatic (M1) disease and its inability to identify locoregional 
metastases limit its reliability. PET seems, however, to detect organ metastases better than 
CT.
In prognostication and treatment allocation for adenocarcinoma of the esophagus/
GEJ, one prerequisite is accurate pretreatment staging. This staging is hoped to be improved 
by the use of PET. We found that adding PET to standard staging does improve detection 
of stage IV disease and its associated poor survival. In sum in locally advanced tumors, 
PET is recommended to exclude patients from unnecessary surgery. Moreover adding 
PET to standard staging does improve detection of stage IV disease and its associated poor 
survival.
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4. Cost-utility of treatment of carcinoma of the esophagus or 
esophagogastric junction
Esophageal carcinoma is one of the deadliest cancer forms known. Its incidence is 
increasing also in Finland (Sihvo et al. 2000, Voutilainen and Juhola 2005). Increased 
resources are needed for its treatment. Our cost-utility analysis shows the incremental 
cost-utility  ratio (ICUR) of the radical surgical treatment was 22 893 € /QALY gained 
compared with palliative treatment according to current practices, which is well below the 
often used threshold of £30 000/QALY (Martin et al. 2003). Our hypothetical model where 
all patients were treated by palliative means was not competitive with current practice. 
Sensitivity analyses showed that in current practice where all eligible patients are treated 
by radical surgery seems to be cost-saving in 46% of the simulated cases, while in 53% 
of the cases more costly and effective compared with palliative treatment for all patients. 
If willingness to pay for a QALY is 30 000 €, the probability of current treatment being 
acceptable is 68%; using a threshold value of 50 000 €, it would be almost 80%.
Radical treatment produces better survival and HRQoL than palliative treatment, 
and consequently, better effi ciency, since the ICUR of  radical treatment compared 
with palliative treatment remain reasonably low despite the cost of treatment in the 
radical group being signifi cantly higher. The sensitivity analysis demonstrates that cost-
effectiveness of treatment of esophageal carcinoma cannot be improved by choosing a 
palliative treatment option for all patients over the current of treatment strategy.
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CONCLUSIONS
Elevated oxidative stress (MPA) and decreased antioxidant defense (GSH) after antirefl ux 
surgery in the distal esophagus indicate that antirefl ux surgery is not a perfect solution for 
oxidative stress of the esophageal mucosa, although it is effective against symptoms and 
macroscopic esophagitis. Elevated oxidative stress may in part explain why adenocarcinoma 
of the distal esophagus is found even after successful fundoplication. 
In GERD patients, proximal esophageal mucosal anti-oxidative defense seems to be 
defective before and even years after successful antirefl ux surgery. In addition, antirefl ux 
surgery seems not to change the level of oxidative stress in the proximal esophagus, 
suggesting that defective mucosal anti-oxidative capacity plays an important role in the 
development of oxidative damage to the esophageal mucosa in GERD.
In the malignant transformation of Barrett’s esophagus, an important component is 
oxidative stress. DNA damage seems to be mediated via 8-OHdG and the entire esophagus 
of Barrett’s patients suffers from increased oxidative stress.
PET is a useful tool in the staging of adenocarcinoma of the esophagus and 
esophagogastric junction because it seems to detects organ metastases better than CT, 
although its accuracy in staging of paratumoral and distant lymph nodes is limited.
Despite its limited accuracy, positive PET for distant metastasis with either positive 
EUS or CT accurately predicts the poor survival of these patients. Adding PET to standard 
staging therefore improves detection of stage IV disease and its associated poor survival.
The current practice in the treatment of esophageal carcinoma where eligible patients 
are treated by radical surgery seems to offer the greatest benefi t in terms of survival and 




Ruokatorven ja mahansuun rauhassyöpä on nopeasti lisääntyvä huonoennusteinen 
sairaus, jonka syntymekanismi on liitetty oksidatiiviseen stressiin. Taudin tarkka kliininen 
levinneisyysluokitus on äärimmäisen tärkeää hoidon onnistumiseksi. Koska tauti on niin 
huonoennusteinen luonteeltaan, ja sen yleisyys lisääntyy nopeasti, on sen hoidon paras 
mahdollinen kustannustehokkuus entistä tärkeämpää. Tämän tutkimuksen tavoitteena oli 
selvittää 1) onko ruokatorven refl uksia estävällä fundoplikaatioleikkauksella ruokatorven 
limakalvon oksidatiivista stressiä vähentävä vaikutus, 2) mikä on oksidatiivisen DNA 
vaurion osuus Barrettin ruokatorven ja ruokatorven rauhassyövän synnyssä, 3) mikä 
on positroniemissiotomografi an (PET) arvo ruokatorven rauhassyövän ennen hoidon 
aloittamista tehtävässä kliinisessä luokituksessa, ja auttaako se taudin ennusteen 
laatimisessa sekä 4) mikä on nykyisen ruokatorven rauhassyövän hoitokäytännön 
kustannustehokkuus.
Ensimmäisessä ja toisessa osatyössä määritimme ruokatorven oksidatiivista 
metaboliaa ruokatorven ylä- ja alapäästä otetuista näytteistä. Oksidatiivisen metabolian 
merkkiaineina toimivat kudoksen myeloperoksidaasi-entsyymin ja superoksidi-
entsyymin aktiivisuus sekä glutathioni-pitoisuus. Ensimmäiset näytteet otettiin ennen 
fundoplikaatioleikkausta ja potilaita seurattiin aina 4 vuoteen asti. Kolmannessa osatyössä 
analysoimme 51 potilaan ruokatorven kudosnäytteistä oksidatiivisen stressin aiheuttamaa 
DNA muutosta, 8-hydroksideoksiguanosiinia (8-OHdG). Neljännessä ja viidennessä 
osatyössä tarkastelimme ensin 42 potilaan ennen leikkaushoitoa tehtyä kliinistä 
levinneisyysluokitusta verrattuna leikkauksen jälkeen tiedossa olevaan patologiseen 
luokitukseen. Jatkoimme edelleen potilaskeräystä aina 55 potilaaseen saakka ja tälle 
joukolle teimme analyysin positroniemissiotomografi an hyödyllisyydestä ennusteen 
laatimiseen. Kuudennessa osatyössä selvitimme ruokatorven syövän kustannuksia ja 
sen hoitoon liittyvää elämänlaatua hoidon eri vaiheissa 53:lla potilaalla. Laadimme 
kustannustehokkuusanalyysin näistä tiedoista.
Tutkimuksemme löydökset olivat seuraavat: 1) onnistunutkaan refl uksinestokirurgia 
ei kykene täysin häivyttämään oksidatiivista stressiä ruokatorven limakalvolta 2) koko 
ruokatorven limakalvon antioksidatiivinen puolustusmekanismi vaikuttaa olevan 
puutteellinen, 3) oksidatiiviseen stressiin liittyvä DNA muutos (8-OHdG) näyttää 
olevan mukana ruokatorven rauhassyövän kehittymisessä, 4) PET parantaa muihin 
elimiin levinneen ruokatorven rauhassyövän toteamista ja näin ollen helpottaa huonon 
ennusteen potilaiden tunnistamista 5) kirurginen, parantamiseen tähtäävä hoito on 
kustannustehokkain vaihtoehto oikein valituille ruokatorven rauhassyöpäpotilaille.
Johtopäätöksinä löydöksistämme on tehtävissä: 1) refl uksinestokirurgia ei pysty 
normalisoimaan oksidatiivisen stressin vaurioittamaa limakalvoa ja näin ollen syövän 
kehittyminen on edelleen mahdollista vialliselle limakalvolle huolimatta toimivasta 
fundoplikaatiosta 2) uusia tutkimuksia tarvitaan - voisiko ruokatorven antioksidatiivista 
puolustusta auttaa refl uksitaudista kärsivillä esim. uusilla lääkeaineilla? 3) todetut 
oksidatiiviset DNA muutokset ruokatorven rauhaskarsinooman synnyssä kannustavat 
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jatkamaan uusissa tutkimuksissa syövän syntymekanismin selvittämistä tältä suunnalta 4) 
PET puoltaa paikkaansa ruokatorven rauhassyövän kliinisessä luokittelussa ja ennusteen 
tunnistamisessa erityisesti huonon ennusteen potilailla. Tämä auttaa resurssien järkevässä 
suuntaamisessa. 5) ruokatorven rauhasyövän parantamiseen tähtäävä kirurginen hoito on 
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